Author: "Urrutia, A." / Topic: business - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Urrutia, A."' showing total 1,723 results

Start Over Author "Urrutia, A." Topic business

1,723 results on '"Urrutia, A."'

1. Analysis of the Business Dimension in the Construction Sector in Ecuador: An Economic Approach

Author: Vayas-Ortega, Germania, Arroba-Naranjo, Dayaneth, Morales-Urrutia, Ximena, Lara-Haro, Diego, Kacprzyk, Janusz, Series Editor, Gomide, Fernando, Advisory Editor, Kaynak, Okyay, Advisory Editor, Liu, Derong, Advisory Editor, Pedrycz, Witold, Advisory Editor, Polycarpou, Marios M., Advisory Editor, Rudas, Imre J., Advisory Editor, Wang, Jun, Advisory Editor, Rocha, Álvaro, editor, Montenegro, Carlos, editor, Pereira, Elisabeth T., editor, Victor, José A. M., editor, and Ibarra, Waldo, editor
Published: 2024
Full Text: View/download PDF

2. The real winner of Venezuela's election urges the regime to face facts

Author: Gonzalez Urrutia, Edmundo
Subjects: Venezuela -- Elections, Electioneering -- Personal narratives, Women politicians -- Political activity, Opposition (Political science) -- Forecasts and trends, Women in politics -- Political activity, Voter turnout -- Forecasts and trends, Political campaigns -- Personal narratives, Contested elections -- Investigations, Presidents -- Elections -- Evaluation, Elections -- Ethical aspects, Company legal issue, Market trend/market analysis, Business, Economics, Business, international
Abstract: I HAVE BEEN been a public servant of Venezuela all my life—a career diplomat whose service culminated during the presidency of Hugo Chávez as ambassador to Argentina. I accepted the [...]
Published: 2024

3. Exploring the use of gender-fair language by influencers

Author: Carolina Nicolas, Angelica Urrutia, and Gonzalo González
Subjects: Inclusive language (IL), Inclusive marketing (IM), Social marketing (SM), Gender-fair language (GFL), Digital content (DC), Marketing analytics (MA), Business, HF5001-6182, Finance, HG1-9999
Abstract: Purpose – Explore the use of Gender-Fair Language (GFL) by influencers on Instagram. Design/methodology/approach – The clustering methodology. A digital Bag-of-Words (BoW) Method called GFL Clustering BoW Methodology to identify whether an inclusive marketing (IM) strategy can be used. Thus, this research has a methodological and practical contribution to increasing the number of marketing technology tools. Findings – This study is original as it proposes an inclusive digital marketing strategy and contributes with methods associated with digital transfers in order to improve marketing strategies, tactics and operations for inclusive content with a data integrity approach. Research limitations/implications – Due to the limitations of the application programming interface (API) of the social network Instagram, a limited number of text data were used, which allowed for retrieving the last 12 publications of each studied profile. In addition, it should be considered that this study only includes the Spanish language and is applied to a sample of influencers from Chile. Practical implications – The practical contribution of this study will lead to a key finding for the definition of communication strategies in both public and private organizations. Originality/value – The originality of this work lies in its attractive implications for nonprofit and for-profit organizations, government bodies and private enterprises in the measurement of the success of campaigns with an IM communicational strategy and to incorporate inclusive and non-sexist content for their consumers so as to contribute to society. 摘要 – 研究目的 – 本研究擬探究有影響力的人士在使用即時電報 (Instagram) 時、如何使用性別中立語言。研究設計/方法/理念 – 研究使用了聚類分析法;具體來說, 研究人員採用一個叫 GFL聚類詞袋法的數位詞袋分析法, 去確定研究可否使用信息管理策略。因此, 本研究在行銷科技方面、添加了一個工具, 就此而言, 本研究在學術的研究法和實務方面、均作出貢獻。研究結果 – 本研究建議了一個包括一切的數位行銷策略;研究亦構建了若干與數位傳輸有關的方法, 以能利用數據完整性的理念, 為行銷策略、行銷戰術和市場營銷, 在內容的全面包含度方面取得改善。研究的局限/啟示 – 因為社交網站即時電報的應用程式介面有其局限, 故使用了少量的文本數據, 這可使每個被探討的傳略的最後12個發佈能被撿回。另外需注意的是、本研究只涵蓋西班牙語, 而且, 研究使用的樣本只是來自智利有影響力的人士。實務方面的啟示 – 本研究在實務方面的貢獻是、它為探討在公共機構和私營機構內使用的溝通策略的定義上、帶來重要的啟發和發現。研究的原創性/價值 – 本研究的原創性在於它給營利和非營利組織、政府機關和私人企業帶來頗具吸引力的啟示。而這些啟示是與測量以包括一切的行銷溝通策略進行的專門活動是否成功有關的。另外, 涵蓋一切和無性別歧視的內容被納入供消費者使用, 以此為社會帶來裨益。
Published: 2023
Full Text: View/download PDF

4. (Opinion) Credit card act is bad news for marginalized communities

Author: Urrutia, Alejandro
Subjects: Political parties -- Laws, regulations and rules, Debit cards -- Laws, regulations and rules, Banking law -- Laws, regulations and rules, Credit card processing services -- Laws, regulations and rules, Hispanic Americans -- Laws, regulations and rules, Government regulation, Business, Business, regional
Abstract: As the former Chairman of the New Hampshire Democratic Party Latino Caucus, I am deeply concerned about how the Credit Card Competition Act could harm the Granite State's underserved communities [...]
Published: 2024

5. Síndrome de Boredom en empresarios familiares del ramo automotriz

Author: Carlos Jesús González Macías, Diego Adiel Sandoval Chávez, Ulises Mendoza Arvizo, and Jesús Alberto Urrutia de la Garza
Subjects: aburrimiento, empresas automotrices, empresa familiar, Commerce, HF1-6182, Business, HF5001-6182
Abstract: El síndrome de Boredom actúa como un cúmulo de emociones propias de sentimientos carentes de estímulo que producen falta de interés, disminución de acción física y falta de concentración hacia las actividades de la empresa. El objetivo de este estudio es aproximar el efecto de este síndrome en empresarios familiares del ramo automotriz en Ciudad Juárez, Chihuahua. Se eligió una aproximación cualitativa por medio de 20 entrevistas a profundidad conducidas con los empresarios y un sondeo de percepción con sus familiares; analizado a la luz de las causas, manifestaciones e influencias propuestas por Gómez y Jiménez (2015), Pekrun et al, (2010), Vogel-Walcutt et al, (2012) y Westgate y Wilson (2018). Los resultados arrojaron una baja de estímulo en los empresarios hacia sus responsabilidades para con la empresa, impulsándolos a desarrollar conductas de gestión que impactan de manera negativa dentro y fuera de ella. Se concluyó que, aunque las habilidades del empresario corresponden a las competencias que desarrollan para llevar a cabo adecuadamente sus actividades dentro de la empresa, estas se ven disminuidas por el boredom, produciendo resultados negativos.
Published: 2023
Full Text: View/download PDF

6. Listening to patients: Opportunities to improve reproductive wellness for women with chronic conditions

Author: Verbiest, Sarah, Cene, Crystal, Chambers, Erica, Pearsall, Marina, Tully, Kristin, and Urrutia, Rachel Peragallo
Subjects: Chronic diseases -- Care and treatment, Pregnant women -- Health aspects, Business, Health care industry
Abstract: Objective: To understand how Black and Native American women with chronic conditions experience reproductive health care and identify patient-centered strategies to improve care. Study Setting and Participants: We held a series of virtual focus groups between February 2021 and December 2021 with 34 women who self-identified as Black or Native American, were of childbearing age, had one or more chronic conditions, and lived in North Carolina. Study Design and Analysis: This qualitative, community-engaged study reviewed notes, video recordings, and graphic illustrations from the focus group sessions. Content analysis was used to iteratively identify themes. Emerging themes were reviewed by community and patient partners. Principal Findings: There were six thematic areas that emerged on the current state of reproductive health care for people with chronic conditions: (1) lack of trust in health care providers and institutions, (2) lack of health care provider knowledge, (3) uncoordinated care, (4) need for self-advocacy, (5) provider bias, and (6) mental health strain from coping. Six approaches for care improvement emerged: (1) build on models of coordinated health care services from other conditions to design more comprehensive care clinics, (2) involve care coordinators or navigators, (3) improve educational materials for patients, (4) train clinicians to increase their capacity to be trustworthy and provide quality, equitable, person-focused care, (5) design scripts to improve clinicians' ability to talk with women about infertility, miscarriage, infant loss, and (6) all interventions and research should be co-designed to address patient priorities. Conclusions: Engaging Black and Native American patient partners with chronic conditions in research planning is feasible, necessary, and beneficial using methods that support connection, respect, and bi-directional learning. Patient partners defined actionable strategies to improve reproductive care and wellness including comprehensive care clinics with patient navigators, trust-enhancing interventions, and better provision of reproductive health related education. KEYWORDS chronic conditions, preconception health, reproductive health, women's health What is known on this topic * Appropriate health care support for managing chronic conditions is important for patients to achieve their desired reproductive health goals and reducing maternal morbidity and mortality. * The reproductive health care system for individuals with chronic conditions is suboptimal, especially for Black and Native American women who experience significant inequities in maternal and reproductive health outcomes. What this study adds * Engaging Black and Native American patient partners with chronic conditions in research planning is feasible, necessary, and beneficial using methods that effectively support connection, respect, and bi-directional learning. * Patient partners defined actionable strategies to improve reproductive care and wellness including comprehensive care clinics with patient navigators, trust-enhancing interventions, and better provision of reproductive health related education. * Having patients lead the way in designing strategies to improve preconception health may result in more culturally responsive and accountable care., 1 | INTRODUCTION Pregnancy-related maternal mortality has been rising in the United States and is currently 17.6 per 100,000 live births. (1) This rate is higher than that in most [...]
Published: 2022
Full Text: View/download PDF

7. Business Growth in Ecuador: A Perspective from Penrose’s Theory of Resources and Capabilities

Author: Morales-Urrutia, Ximena, Salazar-Mera, Juan, Silva-Ordoñez, Catalina, Kacprzyk, Janusz, Series Editor, Pal, Nikhil R., Advisory Editor, Bello Perez, Rafael, Advisory Editor, Corchado, Emilio S., Advisory Editor, Hagras, Hani, Advisory Editor, Kóczy, László T., Advisory Editor, Kreinovich, Vladik, Advisory Editor, Lin, Chin-Teng, Advisory Editor, Lu, Jie, Advisory Editor, Melin, Patricia, Advisory Editor, Nedjah, Nadia, Advisory Editor, Nguyen, Ngoc Thanh, Advisory Editor, Wang, Jun, Advisory Editor, Botto-Tobar, Miguel, editor, Cruz, Henry, editor, and Díaz Cadena, Angela, editor
Published: 2021
Full Text: View/download PDF

8. Decisive Factors of Business Dynamism in Latin America: An Approach from the New Institutional Economy Perspective

Author: Morales-Urrutia, Ximena, Salazar-Mera, Juan, Silva-Ordoñez, Catalina, Kacprzyk, Janusz, Series Editor, Pal, Nikhil R., Advisory Editor, Bello Perez, Rafael, Advisory Editor, Corchado, Emilio S., Advisory Editor, Hagras, Hani, Advisory Editor, Kóczy, László T., Advisory Editor, Kreinovich, Vladik, Advisory Editor, Lin, Chin-Teng, Advisory Editor, Lu, Jie, Advisory Editor, Melin, Patricia, Advisory Editor, Nedjah, Nadia, Advisory Editor, Nguyen, Ngoc Thanh, Advisory Editor, Wang, Jun, Advisory Editor, Botto-Tobar, Miguel, editor, Cruz, Henry, editor, and Díaz Cadena, Angela, editor
Published: 2021
Full Text: View/download PDF

9. Labor Market Policies and Business Cycles in Emerging Economies

Author: Lama, Ruy, Leyva, Gustavo, and Urrutia, Carlos
Subjects: Emerging markets -- Evaluation, Labor market -- Laws, regulations and rules, Business cycles -- Models, Government regulation, Banking, finance and accounting industries, Business, Business, international
Abstract: We build a small open economy business cycle model with search and matching frictions to assess the impact of labor market policies on the dynamics of employment and other macroeconomic variables in emerging economies. The model features an endogenous selection mechanism by which inefficient jobs are destroyed in recessions, thus linking labor market dynamics and aggregate productivity. In a quantitative version of the model calibrated to the Mexican economy, we find that reducing labor taxes and increasing firing costs would have mitigated the fall in employment during the Great Recession of 2008-2009. However, by preventing firms from dismissing low-productive workers, higher firing costs would have impaired this selection mechanism, thus generating a larger fall in TFP and delaying the recovery. Cutting labor taxes, in contrast, have minor effects on productivity by mainly affecting hiring decisions. An extension of the model shows that lowering labor taxes provides an additional productivity boost by expanding formal hirings and reducing the informality rate., JEL Classifications E24 * E32 * F44 * J65 1 Introduction The adjustment of the labor market plays an important role in emerging economies' business cycles. Labor market frictions have [...]
Published: 2022

10. Estrategia de gestión de marca para el ingreso de la panela Panelcauca a segmentos Premium

Author: Adriana Diago Ortiz, Diego Fernando Chávez Narváez, and Rodolfo Andrés Urrutia Bravo
Subjects: gestión de marca, panela, marca, mercadeo y publicidad, Commerce, HF1-6182, Business, HF5001-6182
Abstract: El objetivo de esta investigación es identificar los elementos de la gestión de marca que permitan el diseño de una estrategia para la empresa panelcauca de Colombia con el fin de generar diferenciación y facilitar su ingreso a nuevos segmentos de mercado en los cuales actualmente hay poca competencia. En este sentido, se realiza una investigación cualitativa a través de grupos focales en el segmento de consumidores de alimentos saludables de los estratos 4 y 5 de la ciudad de Cali - Colombia. Se obtiene como resultado el diseño de la estrategia de marca basada en el concepto de dignificación de los paneleros, a partir de este aspecto se definieron los siguientes tres valores de marca: reivindicación del productor y de la panela, conservación del proceso natural en su elaboración y conversión de la panela en el símbolo de la esperanza de miles de familias paneleras del Cauca. Se concluye que el arquetipo de la marca se define como el amigo y el arquetipo de los consumidores como el inocente.
Published: 2020

11. Efficacy of whole-body cryotherapy in the treatment of chronic low back pain: Quasi-experimental study

Author: Krystle Urrutia-García, Oscar Salas-Fraire, Karina Salas-Longoria, Nancy P. Guevara-Neri, Oscar Armando Martínez-Gutiérrez, Juan Antonio Rivera-Pérez, and Rodolfo Morales-Avalos
Subjects: medicine.medical_specialty, business.industry, medicine.medical_treatment, Whole body cryotherapy, Cryotherapy, Chronic low back pain, Oswestry Disability Index, Informed consent, Rating scale, Quasi experimental study, Physical therapy, Medicine, Orthopedics and Sports Medicine, Surgery, In patient, business
Abstract: Single arm, quasi-experimental study design.To describe the effects of whole-body cryotherapy on pain, disability, and serum inflammatory markers in patients with chronic low back pain.A quasi-experimental trial was performed on adult patients between 18 and 65 years with chronic low back pain. After obtaining informed consent, participants underwent 20 sessions of whole-body cryotherapy (at -160 °C) during a 5-week time span. Patient reported pain and disability measures (Pain Numerical Rating Scale [PNRS], Oswestry Disability Index [OSI], and Roland Morris Questionnaire [RMQ]) were obtained at each of the twenty sessions. Blood samples were obtained to analyze serum inflammatory markers at baseline, 10th and 20th session.Forty-one participants were included in the study. A significant decrease was observed between the initial and final PNRS, ODI, and RMQ scores (p 0.001). A significant reduction in the PNRS was found after 4 sessions of whole-body cryotherapy (p 0.001). We observed decreasing values of pro-inflammatory serum marker IL-2 (p = 0.046) and a significant increase in the anti-inflammatory serum marker IL-10 (p = 0.003). No adverse events were reported during the study.Whole-body cryotherapy is an effective therapy for pain and disability treatment in chronic low back pain. It also produces changes in serum markers of inflammation, decreasing pro-inflammatory markers and increasing anti-inflammatory markers.
Published: 2023
Full Text: View/download PDF

12. Systematic mapping on social media and its relation to business

Author: Carolina Nicolas Alarcón, Angélica Urrutia Sepúlveda, Leslier Valenzuela-Fernández, and Jaime Gil-Lafuente
Subjects: Business, HF5001-6182
Abstract: The aim of this study is to analyse the reach of existing investigation on social media and its relation to companies throughout 2014–2015. To achieve the proposed, the study proceeds in classifying such information and identifying methods to study social media and it's relation with different marketing associated topics. The research uses a mapping process that uses the database generated from references of Web of Science's publications during 2014–2015, amounting to 185 articles. The results found that the initial method is a descriptive analysis on the usage of social media as a tool for marketing. Nevertheless, during the past years studies have proposed that social media is becoming more an instrument for marketing and business management. JEL classification: M31, Keywords: Systematic mapping, Social media, Internet, Business, Twitter
Published: 2018
Full Text: View/download PDF

13. Management of anaphylaxis due to COVID-19 vaccines in the elderly

Author: Paulo Augusto Moreira Camargos, Radolslaw Gawlik, Mirko Petrovic, Gunter J. Sturm, Kristof Nekam, Sergio Bonini, Zhanat Ispayeva, Marilyn Urrutia Pereira, Jean Bousquet, Antti Lauerma, Menachem Rottem, Arzu Yorgancioglu, Hubert Blain, Antonio Cherubini, Mário Morais-Almeida, Nathalie Salles, Charlotte G. Mortz, Sylwia Smolinska, Davor Plavec, A. Bedbrook, Torsten Zuberbier, Helga Kraxner, M. Beatrice Bilò, Sinthia Bosnic-Anticevich, Gaëtan Gavazzi, Finbarr C. Martin, Alvaro A. Cruz, K. S. Bennoor, Isabella Annesi-Maesano, Mohamed H. Shamji, Karin Hoffmann-Sommergruber, Marina Atanaskovic-Markovic, Carsten Bindslev-Jensen, Lan Tt Le, Isabel Skypala, Ana Todo-Bom, Vincenzo Patella, Lorenzo Cecchi, Charlotte Suppli Ulrik, Oscar Palomares, Joaquin Sastre, Hans Jürgen Hoffmann, Knut Brockow, Eva Untersmayr, Martin Hrubisko, Bernadette Eberlein, Aziz Sheikh, Milan Sova, Osman M. Yusuf, Violeta Kvedariene, G. Walter Canonica, Dana Wallace, Ioana Agache, Milena Sokolowska, Jos M. G. A. Schols, Susan Waserman, Stéphanie Miot, Carla Irani, Regina E Roller-Winsberger, Michael Levin, Yves Rolland, Emma Montella, Bilun Gemicioglu, Bolesław Samoliński, Stefano Del Giacco, Madda lenaIllario, Yehia El-Gamal, Olga Lourenço, Jean-Christoph Roger J-P Caubet, Luisa Brussino, Marysia Recto, De Yun Wang, Igor Kaidashev, Renaud Louis, Antonino Romano, Mario E. Zernotti, Jacques Reynes, Pedro Carreiro-Martins, Alexandra F. Santos, Marek Niedoszytko, M. Gotua, Musa Khaitov, Thomas B. Casale, Andrea Matucci, Bernardo Sousa-Pinto, Rafael Stelmach, Dejan Dokic, Joana Vitte, Motohiro Ebisawa, Maria Teresa Ventura, Joaquim Mullol, Tomas Chivato, Petr Panzner, Oliver Pfaar, Sanna Toppila-Salmi, Ioanna Tsiligianni, Wytske Fokkens, Alessandra Vultaggio, H. Neffen, Juan Carlos Ivancevich, Ya-dong Gao, Anna Sediva, Maja Hofmann, Ana Maria Carriazo, João Fonseca, Marek Jutel, A. Benetos, Nhân Pham-Thi, Mona Al-Ahmad, Arunas Valiulis, Mihaela Zidarn, Elizabeth Angier, Yoshitaka Okamoto, Montserrat Fernandez-Rivas, Cezmi A. Akdis, Philip W. Rouadi, Olivier Guérin, John Farrell, Mikaela Odemyr, George Christoff, Vera Mahler, Claus Bachert, Edward F. Knol, Wienczyslawa Czarlewski, Robyn E O'Hehir, Victoria Cardona, Ludger Klimek, Tari Haahtela, Vincent Le Moing, Branislava Milenkovic, Carmen Rondon, Kaja Julge, Jolanta Walusiak-Skorupa, Nikolaos G. Papadopoulos, Aslı Gelincik, Markus Ollert, Piotr Kuna, Leyla Namazova-Baranova, Margitta Worm, Annick Barbaud, Elena Camelia Berghea, Todor A. Popov, Derek K. Chu, María José Torres, Faradiba Sarquis Serpa, Nicola Scichilone, Amir Hamzah Abdul Latiff, Frederico S. Regateiro, Gianni Passalacqua, Humboldt-Universität zu Berlin, Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Humboldt University Of Berlin, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Transylvania University, Wrocław Medical University, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], University of Cagliari, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Università Politecnica delle Marche [Ancona] (UNIVPM), Medical Consulting Czarlewski, Universiti Putra Malaysia, University of Southampton, Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), University of Belgrade [Belgrade], Ghent University Hospital, CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Dhaka Shishu Hospital [Bangladesh], University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Odense University Hospital (OUH), Italian National Research Council, National Research Council [Italy] (CNR), The University of Sydney, Technische Universität München = Technical University of Munich (TUM), Università degli studi di Torino = University of Turin (UNITO), Universidade Federal de Minas Gerais = Federal University of Minas Gerais [Belo Horizonte, Brazil] (UFMG), IRCCS Research Hospital, Milan, Vall d'Hebron University Hospital [Barcelona], Centro Hospitalar de Lisboa Central E.P.E, University of South Florida [Tampa] (USF), Geneva University Hospital (HUG), Azienda Usl Toscana centro [Firenze], Софийски университет = Sofia University, McMaster University [Hamilton, Ontario], State University of Bahia, Institute of Public Health of Republic of North Macedonia [Skopje], Ain Shams University (ASU), Sagamihara National Hospital [Kanagawa, Japan], Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), Amsterdam UMC - Amsterdam University Medical Center, Universidade do Porto = University of Porto, Wuhan University [China], CHU Grenoble, Silesian University of Medicine, Istanbul Faculty of Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Centre Hospitalier Universitaire de Nice (CHU Nice), Helsinki University Hospital [Helsinki, Finlande], Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Medizinische Universität Wien = Medical University of Vienna, Aarhus University [Aarhus], Oncology Institute of St Elisabeth, University of Naples Federico II = Università degli studi di Napoli Federico II, St Joseph University, Hôtel-Dieu de France (HDF), Université Saint-Joseph de Beyrouth (USJ), Kazakh National Medical University, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Tartu University Institute of Clinical Medicine, Ukrainina Medical Stomatological Academy [Poltava, Ukraine], Federal Medicobiological Agency [Moscow, Russian Federation], University Medical Center [Utrecht], Semmelweis University [Budapest], Medical University of Łódź (MUL), Vilnius University [Vilnius], University of Medicine and Pharmacy (VIETNAM), University of Cape Town, CHU Sart Tilman, Université de Liège, University of Beira Interior [Portugal] (UBI), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), uBibliorum, Ear, Nose and Throat, AII - Inflammatory diseases, CHU Montpellier, Wroclaw Medical University [Wrocław, Pologne], University of Bari Aldo Moro (UNIBA), Service de Médecine Interne = Hôpital de jour de médecine [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sagamihara National Hospital, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Toulouse [Toulouse], RS: CAPHRI - R1 - Ageing and Long-Term Care, Health Services Research, Bousquet J., Agache I., Blain H., Jutel M., Ventura M.T., Worm M., Del Giacco S., Benetos A., Bilo B.M., Czarlewski W., Abdul Latiff A.H., Al-Ahmad M., Angier E., Annesi-Maesano I., Atanaskovic-Markovic M., Bachert C., Barbaud A., Bedbrook A., Bennoor K.S., Berghea E.C., Bindslev-Jensen C., Bonini S., Bosnic-Anticevich S., Brockow K., Brussino L., Camargos P., Canonica G.W., Cardona V., Carreiro-Martins P., Carriazo A., Casale T., Caubet J.-C., Cecchi L., Cherubini A., Christoff G., Chu D.K., Cruz A.A., Dokic D., El-Gamal Y., Ebisawa M., Eberlein B., Farrell J., Fernandez-Rivas M., Fokkens W.J., Fonseca J.A., Gao Y., Gavazzi G., Gawlik R., Gelincik A., Gemicioglu B., Gotua M., Guerin O., Haahtela T., Hoffmann-Sommergruber K., Hoffmann H.J., Hofmann M., Hrubisko M., Illario M., Irani C., Ispayeva Z., Ivancevich J.C., Julge K., Kaidashev I., Khaitov M., Knol E., Kraxner H., Kuna P., Kvedariene V., Lauerma A., Le L.T.T., Le Moing V., Levin M., Louis R., Lourenco O., Mahler V., Martin F.C., Matucci A., Milenkovic B., Miot S., Montella E., Morais-Almeida M., Mortz C.G., Mullol J., Namazova-Baranova L., Neffen H., Nekam K., Niedoszytko M., Odemyr M., O'Hehir R.E., Okamoto Y., Ollert M., Palomares O., Papadopoulos N.G., Panzner P., Passalacqua G., Patella V., Petrovic M., Pfaar O., Pham-Thi N., Plavec D., Popov T.A., Recto M.T., Regateiro F.S., Reynes J., Roller-Winsberger R.E., Rolland Y., Romano A., Rondon C., Rottem M., Rouadi P.W., Salles N., Samolinski B., Santos A.F., S Sarquis F., Sastre J., M. G. A. Schols J., Scichilone N., Sediva A., Shamji M.H., Sheikh A., Skypala I., Smolinska S., Sokolowska M., Sousa-Pinto B., Sova M., Stelmach R., Sturm G., Suppli Ulrik C., Todo-Bom A.M., Toppila-Salmi S., Tsiligianni I., Torres M., Untersmayr E., Urrutia Pereira M., Valiulis A., Vitte J., Vultaggio A., Wallace D., Walusiak-Skorupa J., Wang D.-Y., Waserman S., Yorgancioglu A., Yusuf O.M., Zernotti M., Zidarn M., Chivato T., Akdis C.A., Zuberbier T., Klimek L., HUS Inflammation Center, University of Helsinki, and Department of Dermatology, Allergology and Venereology
Subjects: Male, Allergy, Pediatrics, Eaaci Position Paper, COVID-19 vaccines, older (adults, GUIDELINES, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Medicine and Health Sciences, Immunology and Allergy, Medicine, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, Geriatrics, MESH: Aged, RISK, Vaccines, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, people), EPINEPHRINE, Epinephrine, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, COVID -19 vaccines, Anaphylaxis, medicine.drug, older (adults/people), medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), MESH: Covid-19, MESH: Epinephrine, Immunology, adrenaline, anaphylaxis, Aged, COVID-19 Vaccines, Humans, SARS-CoV-2, COVID-19, Settore MED/10 - Malattie Dell'Apparato Respiratorio, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Diabetes mellitus, Anaphylaxis/etiology, MESH: SARS-CoV-2, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, COVID‐19 vaccines, Older - Adults/people, Asthma, MESH: Humans, business.industry, adrenaline, anaphylaxis, COVID-19 vaccines, older (adults/people), medicine.disease, Obesity, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, MESH: Male, MESH: Anaphylaxis, Older, 3121 General medicine, internal medicine and other clinical medicine, business, MESH: Covid-19 vaccines, 030215 immunology
Abstract: Submitted by (omml@ubi.pt) on 2021-07-05T10:47:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T10:49:11Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Rejected by Pessoa (pfep@ubi.pt), reason: Rever os nomes dos autores. Depois da correção é só voltar a submeter. on 2021-07-05T10:54:19Z (GMT) Submitted by (omml@ubi.pt) on 2021-07-05T11:52:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T13:34:51Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T13:35:49Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Made available in DSpace on 2021-07-05T13:35:49Z (GMT). No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Previous issue date: 2021-04-02 info:eu-repo/semantics/publishedVersion
Published: 2021
Full Text: View/download PDF

14. Influencia del inicio precoz del tratamiento conservador en la evolución del paciente pediátrico con vejiga neuropática

Author: M.J. Martínez Urrutia, R. Lobato Romera, S. Rivas Vila, P. López Pereira, and L Burgos Lucena
Subjects: medicine.medical_specialty, Urinary continence, medicine.drug_class, business.industry, Urology, Reflux, Renal function, Retrospective cohort study, urologic and male genital diseases, medicine.disease, female genital diseases and pregnancy complications, Surgery, Overactive bladder, Bladder augmentation, medicine, Anticholinergic, Intermittent catheterisation, business
Abstract: Background Clean intermittent catheterization (CIC) and anticholinergic drugs are the mainstay treatment for neuropathic bladder (NB). However, there is not consensus about the time therapy should be started in pediatric patients. Aim To analyze the impact of early start (first year of life) of CIC and anticholinergic treatment on long-term renal and bladder function. Our hypothesis is that those children who start conservative treatment in the first year of life have better outcome in terms of bladder and renal function and less need of surgical procedures, compared to those who started treatment later in life. Patients and method Retrospective study of pediatric patients with NB treated in our hospital (1995-2005) dividing them for comparison in two groups: group 1 started treatment in the first year of life and group 2 between 1 and 5 years old. Collected data included: date of CIC and anticholinergic initiation, presence of VUR or UHN, renal function, UTIs, renal scars, bladder behavior, surgery and urinary continence. Results Sixty-one patients were included, 25 in group 1 and 36 in group 2. Initially vesico-ureteral reflux (VUR) and overactive bladders were more frequent in group 2. In group 1 one overactive bladder changed to low compliant and in group 2, one normal bladder and 4 overactive bladders changed. At the end of follow-up there were 11 low compliant bladders in group 1 and 17 in group 2. However, in group 1, only 2 patients required bladder augmentation (BA) while in group 2, 12 patients needed it. At the end of the study only 2 patients in group 2 had slight renal insufficiency. Conclusions Patients who started conservative treatment in the first year of life have better long-term outcome in terms of UTI, renal scars and surgical procedures. Even if they initially had low compliant bladders, these patients require less BA.
Published: 2022
Full Text: View/download PDF

15. Phase angle is a better indicator of nutritional status than body mass index in patients on hemodialysis

Author: Daniela Meza-Guillén, Carlos A. López-Lozano, Anel V. Barbarín-Vázquez, Jesemil Navarro-Rodríguez, Renato Parra-Michel, Ma. L. Cervantes-Villalobos, Jorge F. Topete-Reyes, Juan Gabriel Juárez-Rojas, Aida Medina-Urrutia, Margarita Torres-Tamayo, Sandra L. López-Báez, and H. Leonardo Pazarín-Villaseñor
Subjects: medicine.medical_specialty, business.industry, medicine.medical_treatment, Internal medicine, Phase angle, medicine, Cardiology, In patient, Nutritional status, General Medicine, Hemodialysis, business, Body mass index
Published: 2023
Full Text: View/download PDF

16. Effects of Subnormothermic Regulated Hepatic Reperfusion on Mitochondrial and Transcriptomic Profiles in a Porcine Model

Author: Jong-In Park, Michael A. Zimmerman, Angela Mathison, David F. Stowe, Catherine Hagen, Joohyun Kim, Amadou K.S. Camara, Gwen Lomberk, Ju Seog Lee, Meiying Yang, Brent T. Boettcher, Joseph E McGraw, Jyotsna Mishra, Johnny C. Hong, Raul Urrutia, Muhammed Ali, Woo Young Shin, and Harvey J. Woehlck
Subjects: Necrosis, business.industry, medicine.medical_treatment, Cellular homeostasis, Liver transplantation, medicine.disease, Cytoplasm organization, Andrology, Transplantation, medicine.anatomical_structure, Apoptosis, Hepatocyte, medicine, Surgery, medicine.symptom, business, Reperfusion injury
Abstract: Objective We sought to investigate the biological effects of pre-reperfusion treatments of the liver after warm and cold ischemic injuries in a porcine donation after circulatory death (DCD) model. Summary of background data DCD represents a severe form of liver ischemia and reperfusion injury that has a profound impact on graft function after liver transplantation. Methods Twenty donor pig livers underwent 60 minutes of in situ warm ischemia after circulatory arrest and 120 minutes of cold static preservation prior to simulated transplantation using an ex vivo perfusion machine. Four reperfusion treatments were compared: Control-Normothermic (N), Control-Subnormothermic (S), regulated hepatic reperfusion (RHR)-N, and RHR-S (n = 5 each). The biochemical, metabolic, and transcriptomic profiles, as well as mitochondrial function were analyzed. Results Compared to the other groups, RHR-S treated group showed significantly lower post-reperfusion aspartate aminotransferase levels in the reperfusion effluent and histologic findings of hepatocyte viability and lesser degree of congestion and necrosis. RHR-S resulted in a significantly higher mitochondrial respiratory control index and calcium retention capacity. Transcriptomic profile analysis showed that treatment with RHR-S activated cell survival and viability, cellular homeostasis as well as other biological functions involved in tissue repair such as cytoskeleton or cytoplasm organization, cell migration, transcription, and microtubule dynamics. Furthermore, RHR-S inhibited organismal death, morbidity and mortality, necrosis, and apoptosis. Conclusion Subnormothermic RHR mitigates IRI and preserves hepatic mitochondrial function after warm and cold hepatic ischemia. This organ resuscitative therapy may also trigger the activation of protective genes against IRI. Subnormothermic RHR has potential applicability to clinical liver transplantation.
Published: 2023

17. Combination of olanzapine with bispectral index guided anesthesia to prevent postoperative delirium in elderly patients undergoing major gastrointestinal elective surgery: a randomized, double-blind, placebo-controlled study protocol

Author: Raquel Costa, Osama Alzobi, Diego Arbaje, Veronica Hernandez Leon, Flavia Tarcha, Jannis Müller, Eleonora Boschetti Grutzmacher, Ibnouf Sulieman, Eman Youssif, Diego Noya Rabelo, Pedro Hilton de Andrade Filho, Catherine Skinner, Maria Belen Cubria, Juliana Tepedino Martins Alves, Muhammad Haseeb, Brahim Khouri Lopez, Aline Marcadenti, Denise Saretta Schwartz, Salim Al-Busaidi, Diego Daniel Garcia Choza, Denisse Castro, Annette García Delgado, Gabriela Casais, Victor Batistella, Francisca Urrutia Goldsack, Arturo Tamayo, and Moyses Cohen
Subjects: Olanzapine, medicine.medical_specialty, business.industry, medicine.medical_treatment, Placebo-controlled study, Placebo, Anesthesia, Bispectral index, medicine, Delirium, Neurosurgery, Elective surgery, medicine.symptom, Antipsychotic, business, medicine.drug
Abstract: Introduction: Postoperative delirium (POD) is an important complication of major surgery in elderly patients. It increases morbidity and mortality, hospital stay, and total healthcare costs. Since no treatment has proven effective once POD is established, prevention is key. Evidence exists that bispectral index guided anesthesia (BIS-GA) and antipsychotics may independently reduce incidence of POD, but the efficacy of combining these preventive strategies is unknown. Objective: To compare the combination of olanzapine + BIS-GA with BIS-GA alone for prevention of POD in elderly patients undergoing major elective surgery.Methods: We propose a Phase II, multi-center, randomized, double-blind, parallel, placebo-controlled trial. The study arms will be BIS-GA + two doses of olanzapine 5mg given pre and postoperatively compared with BIS-GA + placebo in patients ≥65 years hospitalized for major elective surgery. Exclusion criteria include cardiac- and neurosurgery, dementia history, concurrent antipsychotic, anticholinergic, or sedative-hypnotic use, olanzapine allergy, delirium at hospital admission, cognitive impairment and inability to be interviewed. The primary outcome is incidence of POD diagnosed by DSM-V criteria and assessed by the Confusion Assessment Method (CAM) scale. Secondary outcomes include delirium severity, rescue therapy use, length of hospital stay and incidence of adverse events.Discussion: There is an increasing need for trials that advance knowledge in prophylactic methods to prevent delirium. By combining two preventive methods, we expect to decrease the incidence of POD, which will result in decreased morbidity, mortality, and total healthcare costs.
Published: 2021
Full Text: View/download PDF

18. The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions

Author: Julian E. Garcia, Melissa A. Daubert, Craig R. Lee, Matthew Shane Loop, Ian R. Mulrenin, Muluneh M. Fashe, and Rachel Peragallo Urrutia
Subjects: medicine.medical_specialty, Nifedipine, medicine.drug_class, Toxicology, Article, Pharmacokinetics, Pregnancy, Humans, Medicine, Labetalol, Dosing, Antihypertensive drug, Intensive care medicine, Antihypertensive Agents, Pharmacology, business.industry, Hypertension, Pregnancy-Induced, General Medicine, medicine.disease, Bioavailability, Pharmaceutical Preparations, Gestation, Female, business, medicine.drug
Abstract: INTRODUCTION: Hypertensive disorders of pregnancy (HDP) are rising in prevalence, and increase risk of adverse maternal and fetal outcomes. Physiologic changes occur during pregnancy that alter drug pharmacokinetics. However, antihypertensive drugs lack pregnancy-specific dosing recommendations due to critical knowledge gaps surrounding the extent of gestational changes in antihypertensive drug pharmacokinetics and underlying mechanisms. AREAS COVERED: This review (1) summarizes currently recommended medications and dosing strategies for non-emergent HDP treatment, (2) reviews and synthesizes existing literature identified via a comprehensive Pubmed search evaluating gestational changes in the maternal pharmacokinetics of commonly prescribed HDP drugs (notably labetalol and nifedipine), and (3) offers insight into the metabolism and clearance mechanisms underlying altered HDP drug pharmacokinetics during pregnancy. Remaining knowledge gaps and future research directions are summarized. EXPERT OPINION: A series of small pharmacokinetic studies illustrate higher oral clearance of labetalol and nifedipine during pregnancy. Pharmacokinetic modeling and preclinical studies suggest these effects are likely due to pregnancy-associated increases in hepatic UGT1A1- and CYP3A4-mediated first-pass metabolism and lower bioavailability. Accordingly, higher and/or more frequent doses may be needed to lower blood pressure during pregnancy. Future research is needed to address various evidence gaps and inform the development of more precise antihypertensive drug dosing strategies.
Published: 2021
Full Text: View/download PDF

19. Precision medicine in trauma: a transformational frontier in patient care, education, and research

Author: Gwen Lomberk, Christina Georgeades, Nathaniel James Carpenter, Katheryn Hope Wilkinson, Raul Urrutia, Christopher S. Davis, and Emily Lin
Subjects: Epigenomics, medicine.medical_specialty, Genomics, Review Article, Critical Care and Intensive Care Medicine, Intervention (counseling), medicine, Humans, Orthopedics and Sports Medicine, Intensive care medicine, Cause of death, business.industry, Precision medicine, Trauma surgery, Personalized medicine, United States, Pharmacogenomics, Emergency Medicine, Surgery, Patient Care, business
Abstract: Purpose Trauma is the leading cause of death before the age of 45 in the United States. Precision medicine (PM) is the most advanced scientific form of medical practice and seeks to gather data from the genome, environmental interactions, and lifestyles. Relating to trauma, PM promises to significantly advance our understanding of the factors that contribute to the physiologic response to injury. Methods We review the status of PM-driven trauma care. Semantic-based methods were used to gather data on genetic/epigenetic variability previously linked to the principal causes of trauma-related outcomes. Data were curated to include human investigations involving genomics/epigenomics with clinical relevance identifiable early after injury. Results Most studies relevant to genomic/epigenomic differences in trauma are specific to traumatic brain injury and injury-related sepsis. Genomic/epigenomic differences rarely encompass other relevant factors, such as coagulability and pharmacogenomics. Few studies describe clinical use of genomics/epigenomics for therapeutic intervention in trauma care, and even fewer attempt to incorporate real-time genomic/epigenomic information to precisely guide clinical decision-making. Conclusion Considering that genomics/epigenomics, environmental exposures, and lifestyles are most likely to be of significant medical relevance in advancing the field of trauma, the lack of application of concepts and methodologies from PM to trauma education, research, practice, and community wellness is underwhelming. We suggest that significant effort be given to incorporate the tools of what is becoming the “new medicine”.
Published: 2021

20. La experiencia de implementar una historia clínica electrónica en siete centros en menos de un año

Author: Ariel L. Fernández, Miguel Angel Urrutia, Walter Maestri, Mercedes Salomé Agostinelli, and María P. Arias López
Subjects: Process management, Computer science, business.industry, Process (engineering), Health care, Digital transformation, Electronic medical record, Organizational culture, General Medicine, Quality of care, business, Multidisciplinary team
Abstract: Introducción: Extensa evidencia publicada sugiere que la implementación de una historia clínica electrónica (HCE) tiene potencial de mejorar la calidad de la atención, disminuyendo errores médicos causados por falta de coordinación, comunicación, pérdida de información, etc. Las dificultades encontradas en el proceso de informatización varían según la infraestructura local. Nuestro objetivo es describir un modelo de implementación exitoso de una HCE en un medio con un grado de informatización institucional y regional heterogéneo que pueda resultar útil en similares escenarios. Métodos: Descripción de una implementación llevada a cabo por un equipo multidisciplinario, utilizando un proceso estandarizado y un modelo sustentado en compromiso y apoyo de los referentes institucionales, comunicación efectiva del proyecto a todos los actores, planificación del entrenamiento y monitoreo de las etapas predefinidas. Resultados: El modelo de implementación descripto permitió poner en producción una HCE en menos de un año en siete centros (ambulatorios e internación). Más de 2000 usuarios recibieron entrenamiento personalizado en su ámbito de trabajo, focalizado en sus necesidades. El éxito de la implementación radicó en alcanzar el compromiso del nivel ejecutivo y de los líderes locales sumado a una adecuada planificación y a la adaptación del modelo a la cultura organizacional. Disponer de un equipo de implementación para brindar a los usuarios soporte en tiempo y forma y adecuado a sus necesidades fue también clave para el éxito del proceso. Conclusiones: La implementación de una HCE usando un modelo estandarizado permitió disminuir la variabilidad del proceso, mejorar los resultados finales y dejar la estructura preparada para continuar ampliando la informatización de los centros.
Published: 2021
Full Text: View/download PDF

21. Antidepressants and Black Box Warning: Duty to Inform or Unintended Consequence of Cautious Response

Author: Hanife Akal, Ainsley Backman, Sadiq Naveed, Victoria Urrutia, Muhammad Zeshan, and Salma Malik
Subjects: Black box (phreaking), Psychiatry and Mental health, business.industry, media_common.quotation_subject, Medicine, Advertising, business, Duty, media_common
Abstract: Suicide is a global health problem. According to the World Health Organization, more than 700,000 people a year die because of suicide. About 90% of suicides in the United States are associated with a psychiatric illness, with major depressive disorder (MDD) accounting for 50% of these cases. Although antidepressants are the preferred choice for the treatment of MDD with or without suicidal ideations, they can cause worsening of suicidal ideations in some cases. In October 2004, the US Food and Drug Administration (FDA) directed manufacturers of all antidepressants to add a “black box” warning regarding possible worsening suicidal thoughts and behaviors in patients younger than age 18 years. In 2006, the FDA extended this warning to young adults up to age 24 years. Since then, there has been significant discussion regarding the warning, its merits and impact, and the implications on the use of antidepressants for the effective management of MDD. This article reviews the historical background of the black box warning, existing evidence, and recommendations on effectively communicating with children/adolescents and their caregivers. [ Psychiatr Ann . 2021;51(10):467–472.]
Published: 2021
Full Text: View/download PDF

22. Routine Biomarkers for the Severity of COVID-19 Pneumonia May Present Differently in Kidney Transplant Recipients

Author: Javier Paul-Martinez, Ricardo Lauzurica, Elena Burgos, Omar Taco, Judit Cacho, Marina Urrutia-Jou, Fredzzia Graterol, María Molina, Inés Perezpayá, Javier Juega, and Laura Cañas
Subjects: Male, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Lymphocyte, Gastroenterology, Article, Interquartile range, Internal medicine, medicine, Humans, Aged, Transplantation, biology, business.industry, Hazard ratio, COVID-19, Pneumonia, Middle Aged, medicine.disease, Kidney Transplantation, Confidence interval, Ferritin, medicine.anatomical_structure, biology.protein, Etiology, Female, Surgery, business, Biomarkers
Abstract: Background The treatment of coronavirus disease 2019 (COVID-19) is based on the patient's clinical status and levels of inflammatory biomarkers. The comparative activity of these biomarkers in kidney transplant (KT) patients with COVID-19 pneumonia from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and non–SARS-CoV-2 etiologies is unknown. The aim of this study was to compare the clinical presentation and inflammatory parameters at admission of KT patients with COVID-19 pneumonia and those with non–COVID-19 pneumonia over the same period. Methods Biomarkers were measured and compared between KT patients with COVID-19 pneumonia (n = 57) and non-COVID-19 pneumonia (n = 20) from March 2020 to March 2021. Results Both groups showed comparable demographics. The KT patients with COVID-19 had fewer neutrophils (6824 ± 5000 vs 8969 ± 4206; P = .09) than the non-COVID group, although there was no significant difference in the lymphocyte count. Non–COVID-19 pneumonia was associated with higher d -dimer (median, 921 [interquartile range (IQR), 495-1680] vs median, 2215 [IQR, 879-3934]; P = 0.09) and interleukin-6 (median, 35 [IQR, 20-128] vs median, 222 [IQR, 38-500]; P = 0.006) levels. The ferritin level was higher in the COVID-19 group (median, 809 [IQR, 442-1,330] vs median, 377 [IQR, 276-885]; P = 0.008). In multivariable analysis, only d -dimer (hazard ratio [HR], 1; 95% confidence interval [CI],1-1.002; P = .02) and ferritin (HR, 1; 95% CI, 0.9-0.9; P = .02) increase the statistic signification. Conclusion COVID-19 pneumonia in KT patients shows a different presentation of inflammatory biomarkers than other non-COVID pneumonias. It could be useful to identify KT patients with COVID-19. More detailed studies are necessary to understand the presentation of biomarkers in KT with COVID-19.
Published: 2021
Full Text: View/download PDF

23. Degludec hospital trial: A randomized controlled trial comparing insulin degludec <scp>U100</scp> and glargine <scp>U100</scp> for the inpatient management of patients with type 2 diabetes

Author: Priyathama Vellanki, David W. Lam, Katherine R. Tuttle, Rodolfo J. Galindo, Maria A. Urrutia, Karla Walkiria Zamudio-Coronado, Limin Peng, Georgia Davis, Maya Fayfman, Citlalli Perez-Guzman, Radica Z. Alicic, Guillermo E. Umpierrez, Alexandra Migdal, Saumeth Cardona, and Francisco J. Pasquel
Subjects: Blood Glucose, Insulin degludec, medicine.medical_specialty, Randomization, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Insulin Glargine, Type 2 diabetes, Article, law.invention, Endocrinology, Randomized controlled trial, law, Internal medicine, Internal Medicine, medicine, Clinical endpoint, Humans, Hypoglycemic Agents, Prospective Studies, Glycated Hemoglobin, Inpatients, business.industry, Insulin, medicine.disease, Hospitals, Insulin, Long-Acting, Regimen, Diabetes Mellitus, Type 2, Basal (medicine), business
Abstract: AIMS: Limited data exists about the use of insulin degludec in the hospital. This multicentre, non-inferiority, open-label, prospective randomised trial compared the safety and efficacy of insulin degludec-U100 and glargine-U100 for the management of hospitalized patients with type 2 diabetes. METHODS: A total of 180 general medicine and surgery patients with an admission blood glucose (BG) between 7·8 – 22·2 mmol/L, treated with oral agents or insulin prior to hospitalization were randomly allocated (1:1) to a basal bolus regimen using degludec (n=92) or glargine (n=88), as basal and aspart before meals. Insulin dose was adjusted daily to a target BG between 3·9 – 10·0 mmol/L. The primary end point was difference in the mean hospital daily BG between groups. RESULTS: Overall, the randomization BG was 12·2 ± 2·9 mmol/L and HbA1c 84 mmol/mol (9·8±2·0%). There were no differences in mean daily BG (10·0±2·1 vs. 10·0±2·5 mmol/L, p=0·9), proportion of BG in target range (54·5± 29% vs. 55·3 ± 28%, p=0·85), basal insulin (29·6 ± 13 vs 30·4 ± 18 units/day, p=0·85), length of stay (median (IQR): 6·7 (4·7–10·5) vs. 7·5 (4·7–11·6) days, p=0·61), hospital complications (23% vs. 23%, p=0·95) between treatment groups. There were no differences in the proportion of patients with BG
Published: 2021
Full Text: View/download PDF

24. Organizational learning culture in industry 4.0: relationships with work engagement and turnover intention

Author: Giovana Urrutia Pereira, Manoela Ziebell de Oliveira, and Wagner de Lara Machado
Subjects: Organizational Behavior and Human Resource Management, Industry 4.0, business.industry, Work engagement, Organizational learning, Turnover intention, Digital transformation, Information technology, Public relations, business, Psychology, Adaptation (computer science), Period (music)
Abstract: The period of digital transformation that we are experiencing, called Industry 4.0, has marked a series of changes in the way we relate as a society, requiring constant adaptation and new knowledge...
Published: 2021
Full Text: View/download PDF

25. Aplasia congénita unilateral del cartílago alar

Author: F Alfredo Urrutia, C Daniel Cantero, M Jaime Osorio, and D Angélica Suazo
Subjects: business.industry, Medicine, General Medicine, Anatomy, Aplasia, business, medicine.disease
Published: 2021
Full Text: View/download PDF

26. Systemic Adverse Reactions to Psychotropic Medications: What Do We Need to Know?

Author: Lovejit Kaur, Salma Malik, Sadiq Naveed, Victoria Urrutia, and Justin Marshall
Subjects: Psychiatry and Mental health, medicine.medical_specialty, business.industry, Need to know, Medicine, business, Intensive care medicine
Abstract: This article focuses on potential systemic adverse reactions secondary to use of psychotropic agents. Clinicians, at times, have to manage these relatively uncommon systemic side effects. If not managed in a timely manner, these side effects could contribute to morbidity and mortality. This article reviews the prevalence, neurobiological underpinning, course, diagnosis, management, and prognosis of serotonin syndrome, neuroleptic malignant syndrome, lithium toxicity, antiepileptic hypersensitivity reactions (DRESS syndrome and Stevens-Johnson syndrome), and discontinuation syndromes. Prescribers need to be cognizant and should be knowledgeable in understanding and managing these potential systemic side effects. [ Psychiatr Ann . 2021;51(9):421–426.]
Published: 2021
Full Text: View/download PDF

27. Impact of fiscal incentives in the consumption of low emission vehicles

Author: Jorge Fábrega and Jorge Urrutia-Mosquera
Subjects: Consumption (economics), 050210 logistics & transportation, Low emission vehicle, Public economics, media_common.quotation_subject, 05 social sciences, Geography, Planning and Development, 0211 other engineering and technologies, 021107 urban & regional planning, Transportation, 02 engineering and technology, Payment, Purchasing, Urban Studies, Incentive, Willingness to pay, Mixed logit, 0502 economics and business, Business, Hybrid vehicle, media_common
Abstract: Due to the high emissions produced by the transportation sector, one of the most implemented policies worldwide is the economic incentive to purchase electric and hybrid vehicles. The adoption of these policies in developing countries is scarce or null and there are no studies that investigate the impact of economic incentives in the potential demand for low emission vehicles. This paper covers this gap. Using data from a stated preference experiment in Santiago of Chile, specifically built to collect individuals’ preferences for incentives to low emission vehicles, a mixed logit model was estimated and results used to compute willingness to pay. In parallel, a contingent evaluation experiment was conducted to elicit individuals’ willingness to pay under two specific policies, involving different ways to provide fiscal incentives. Results shows that individuals are more sensitive to autonomy and incentives in the case of electric vehicles in relation to conventional/hybrid type. Likewise, results show that for an exemption from VAT payment and any type of sales and purchase tax, 72% of individuals would be willing to purchase an electric vehicle, and 76% of individuals would be willing to purchase a hybrid vehicle, waiting for an adequate incentive policy for it.
Published: 2021
Full Text: View/download PDF

28. Consensus on the treatment of allergic asthma with sublingual house dust mite immunotherapy in the field of pneumology

Author: José María Ignacio, Isabel Urrutia, Vicente Plaza, Marina Blanco-Aparicio, and Aurelio Arnedillo
Subjects: Pulmonary and Respiratory Medicine, Allergy, medicine.medical_specialty, mites, Consensus, medicine.medical_treatment, Disease, sublingual, immune system diseases, Pulmonary Medicine, medicine, Animals, Humans, Immunology and Allergy, In patient, Sublingual immunotherapy, Antigens, Dermatophagoides, Asthma, House dust mite, Sublingual Immunotherapy, biology, business.industry, Pyroglyphidae, Public Health, Environmental and Occupational Health, Allergic asthma, Immunotherapy, asthma, medicine.disease, biology.organism_classification, Dermatology, respiratory tract diseases, subcutaneous, immunotherapy, business
Abstract: Introduction: Many patients sensitized to mites remain symptomatic and uncontrolled despite traditional treatment. Sublingual immunotherapy (SLIT) has demonstrated to reduce the symptoms of allergic rhinitis, the need for additional drug treatments, and to reduce the number of moderate and severe exacerbations in patients with allergic asthma caused by mites that had not been adequately controlled. Areas covered: After reviewing the most recent literature, a scientific committee composed by five pneumologists experts in asthma proposed 41 items that addressed the diagnosis of allergic asthma caused by mites, the role of house dust mite (HDM) SLIT tablet in the therapeutic plan and in the control of the disease, and the profile of patients with asthma candidates for this therapy. Through a modified Delphi method, the items were send to 106 pneumologists involved in asthma to be agreed. Expert opinion: The high degree of consensus reached by the panel of pneumologists shows the importance of HDM SLIT tablet in the treatment of allergic asthma caused by mites, particularly taking into account that they barely use this therapy because until now they did not have a registered treatment with solid evidence of efficacy and safety.
Published: 2021
Full Text: View/download PDF

29. An independent inter- and intra-observer agreement assessment of the Eno classification of sacroiliac joint degeneration

Author: Pablo Cikutovic, Marcelo Valacco, Gaston Camino-Willhuber, Julio Urrutia, Matias Borensztein, Nelson Astur, and Osvaldo Velan
Subjects: Scoring system, Computed tomography, 03 medical and health sciences, 0302 clinical medicine, Cohen's kappa, Ankylosis, Humans, Medicine, Radiology, Nuclear Medicine and imaging, Observer Variation, Sacroiliac joint, 030222 orthopedics, Radiological and Ultrasound Technology, medicine.diagnostic_test, business.industry, Reproducibility of Results, Sacroiliac Joint, General Medicine, medicine.disease, Intra observer, Clinical Practice, medicine.anatomical_structure, Tomography, X-Ray Computed, business, Nuclear medicine, 030217 neurology & neurosurgery, Kappa
Abstract: Background Recently, a scoring system to grade sacroiliac joint (SIJ) degeneration using computed tomography (CT) scans was described. No independent evaluation has determined the inter- and intra-observer agreement using this scheme. Purpose To perform an independent inter- and intra-observer agreement assessment using the Eno classification and determining gas in the SIJ. Material and Methods We studied 64 patients aged ≥60 years who were evaluated with abdominal and pelvic computed tomography scans. Six physicians (three orthopaedic spine surgeons and three musculoskeletal radiologists) assessed axial images to grade SIJ degeneration into grade 0 (normal), grade 1 (mild degeneration), grade 2 (significant degeneration), and grade 3 (ankylosis). We also evaluated the agreement assessing the presence of gas in the SIJ. After a four-week interval, all cases were presented in a random sequence for repeat assessment. We determined the agreement using the kappa (κ) or weighted kappa coefficient (wκ). Results The inter-observer agreement was moderate (wκ = 0.50 [0.44–0.56]), without differences among surgeons (wκ = 0.53 [0.45–0.61]) and radiologists (wκ = 0.49 [0.42–0.57]). The agreement evaluating the presence of gas was also moderate (κ = 0.45 [0.35–0.54]), but radiologists obtained better agreement (κ = 0.61 [0.48–0.72]) than surgeons (κ = 0.29 [0.18–0.39]). The intra-observer agreement using the classification was substantial (wκ = 0.79 [0.76–0.82]), without differences comparing surgeons (wκ = 0.75 [0.70–0.80]) and radiologists (wκ = 0.83 [0.79–0.87]). The intra-rater agreement evaluating gas was substantial (κ = 0.77 [0.72–0.82]), without differences between surgeons (κ = 0.71 [0.63–0.78]) and radiologists (κ = 0.84 [0.78–0.90]). Conclusion Given the only moderate agreement obtained using the Eno classification, it does not seem adequate to be used in clinical practice or in research.
Published: 2021
Full Text: View/download PDF

30. Correlation between 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET in patients with Parkinson’s disease: a pilot study

Author: Julieta E. Arena, Leandro Urrutia, Germán Falasco, Magdalena Ponce de Leon, Silvia Vazquez, Malco Rossi, and Marcelo Merello
Subjects: 0301 basic medicine, Movement disorders, Parkinson's disease, 99mtc trodat 1, R895-920, Positron-emission tomography/methods, Dihydroxyphenylalanine/analogs & derivatives, Correlation, Medical physics. Medical radiology. Nuclear medicine, 03 medical and health sciences, 0302 clinical medicine, 18f fdopa, medicine, Radiology, Nuclear Medicine and imaging, In patient, Fluorodopa, Tomography, emission-computed, single-photon/methods, medicine.diagnostic_test, business.industry, medicine.disease, 030104 developmental biology, Tropanes/pharmacokinetics, Parkinson disease/diagnostic imaging, medicine.symptom, Nuclear medicine, business, Parkinsonian disorders/diagnostic imaging, 030217 neurology & neurosurgery, Emission computed tomography
Abstract: Objective: To determine whether technetium-99m-labeled tropane derivative single-photon emission computed tomography (99mTc-TRODAT-1 SPECT) provides results comparable to those of the less widely available, less accessible tool fluorine-18-labeled fluorodopa positron-emission tomography (18F-FDOPA PET) in the setting of a movement disorders clinic. Materials and Methods: In this prospective pilot study, eight subjects with a clinical diagnosis of Parkinson’s disease were randomly selected from among patients under treatment at a movement disorders clinic and submitted to 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET. The results were read by two experienced observers, and a semiquantitative analysis was performed. Results: The visual and semiquantitative analyses were concordant for all studies, showing that radiotracer uptake in the contralateral striatum on the most affected side was lower when 99mTc-TRODAT-1 SPECT was employed. The semiquantitative analysis demonstrated a significant correlation between 18F-FDOPA PET and 99mTc-TRODAT-1 SPECT (r = 0.73; p < 0.01). Conclusion: It appears that 99mTc-TRODAT-1 SPECT is a valid option for the study of dopaminergic function in a clinical setting.
Published: 2021
Full Text: View/download PDF

31. Dust from the Sahara to the American Continent: Health impacts

Author: Herberto José Chong-Neto, Marilyn Urrutia-Pereira, Patrícia Latour Staffeld, Giovanni Viegi, Luciana V. Rizzo, and Dirceu Solé
Subjects: Pulmonary and Respiratory Medicine, Pollution, Mediterranean climate, Saharan Air Layer, medicine.medical_specialty, Amazon rainforest, business.industry, media_common.quotation_subject, Public health, Immunology, General Medicine, Mineral dust, complex mixtures, Atmosphere, medicine, Immunology and Allergy, Physical geography, business, Air mass, media_common
Abstract: The Saharan Air Layer is a mass of hot, dry air laden with dust that forms over the Sahara and moves towards the Atlantic Ocean. This air mass contains soil dust particles emitted by the action of winds on the African continent. Between June and August, the large-scale patterns of wind circulation transport dust from the Sahara across the tropical North Atlantic Ocean,affecting parts of the Caribbean, Central America, Mexico, even some regions of the United States, and the Mediterranean and Southern Europe. Between December and April, wind circulation patterns facilitate dust transportation from the Sahara to the northern parts of South America and the Amazon. This dust transportation a phenomenon of interest to geosciencesand public health because of the potential health impacts of dust dispersion and circulation in the atmosphere. Thus, we assessed the relationship between exposure to Saharan dust (SahD) and its implications for human health in the Americas. We performed a nonsystematic review in the PubMed, Google Scholar, EMBASE, and Scielo databases of studies published between 2000 and 2020 in Portuguese, English, French, or Spanish using the search words “Saharan dust,” or “mineral dust,” or “desert dust,” and “human health.” The available direct air pollutants measurements indicate that the pollution level in the cities affected on a constant and prolonged basis is high versus acceptable standards. Further, this review also showed that the negative health effects of SahD are sparsely studied in the Americas.
Published: 2021
Full Text: View/download PDF

32. Accuracy of Dexcom G6 Continuous Glucose Monitoring in Non–Critically Ill Hospitalized Patients With Diabetes

Author: Alexandra Migdal, Rodolfo J. Galindo, Georgia Davis, Kashif M. Munir, William H. Scott, Rebecca M. Doerfler, Sergio Lizama, Medha Satyarengga, Francisco J. Pasquel, Lakshmi G. Singh, Maria A. Urrutia, Priyathama Vellanki, Bonnie S. Albury, Guillermo E. Umpierrez, Saumeth Cardona, K. Walkiria Zamudio-Coronado, Elias K. Spanakis, and Limin Peng
Subjects: Research design, Blood Glucose, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Type 2 diabetes, Hypoglycemia, Interquartile range, Diabetes management, Diabetes mellitus, Internal medicine, Emerging Technologies: Data Systems and Devices, Internal Medicine, medicine, Humans, Aged, Retrospective Studies, Advanced and Specialized Nursing, business.industry, Insulin, Blood Glucose Self-Monitoring, Reproducibility of Results, Middle Aged, medicine.disease, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Ambulatory, business
Abstract: OBJECTIVE Advances in continuous glucose monitoring (CGM) have transformed ambulatory diabetes management. Until recently, inpatient use of CGM has remained investigational, with limited data on its accuracy in the hospital setting. RESEARCH DESIGN AND METHODS To analyze the accuracy of Dexcom G6, we compared retrospective matched-pair CGM and capillary point-of-care (POC) glucose data from three inpatient CGM studies (two interventional and one observational) in general medicine and surgery patients with diabetes treated with insulin. Analysis of accuracy metrics included mean absolute relative difference (MARD), median absolute relative difference (ARD), and proportion of CGM values within 15, 20, and 30% or 15, 20, and 30 mg/dL of POC reference values for blood glucose >100 mg/dL or ≤100 mg/dL, respectively (% 15/15, % 20/20, % 30/30). Clinical reliability was assessed with Clarke error grid (CEG) analyses. RESULTS A total of 218 patients were included (96% with type 2 diabetes) with a mean age of 60.6 ± 12 years. The overall MARD (n = 4,067 matched glucose pairs) was 12.8%, and median ARD was 10.1% (interquartile range 4.6, 17.6]. The proportions of readings meeting % 15/15, % 20/20, and % 30/30 criteria were 68.7, 81.7, and 93.8%, respectively. CEG analysis showed 98.7% of all values in zones A and B. MARD and median ARD were higher in the case of hypoglycemia ( CONCLUSIONS Our results indicate that CGM technology is a reliable tool for hospital use and may help improve glucose monitoring in non–critically ill hospitalized patients with diabetes.
Published: 2021

33. Hospital admission for symptoms exacerbation in 2,075 infants suffering from recurrent asthma-like symptoms (EISL-3 South America)

Author: Javier Mallol, Dirceu Solé, Carolina Aranda, Eliana C. Toledo, Viviana Aguirre, Marilyn Urrutia-Pereira, Gabriela A. Szulman, Nelson Rosario, Herberto Chong, Líllian Sanchez-Lacerda, Jurg Niederbacher, Catalina Pinchak, Patricia Polles de Olivera, Erika Arruda-Chávez, Luis García-Marcos, and null EISL Phase 3 Study Group South America
Subjects: Pulmonary and Respiratory Medicine, Pediatrics, medicine.medical_specialty, Pregnancy, Exacerbation, business.industry, Immunology, Breastfeeding, General Medicine, Prenatal smoking, medicine.disease, Logistic regression, South american, Hospital admission, medicine, Immunology and Allergy, business, Asthma
Abstract: Background: Contrary to what happens in children and adults, the prevalence and the factors related to hospitalisation for asthma/wheezing in infants with recurrent asthma-like symptoms are poorly known.Methods: This study is part of the International Study of Wheezing in infants Phase 3; 2,079 infants (aged 12–18 months) with recurrent asthma-like symptoms, from 11 South American centres, were studied to determine the prevalence and the associated factors for wheezing exacerbation admission. Descriptive statistics and multivariate logistic regression were employed for analysis.Results: The prevalence of admission for wheezing was 29.7% (95% CI 27.7–31.6) and was significantly associated to severe wheezing episodes (OR: 3.89; 95% CI: 2.93–5.18, p < 0.001), physician-diagnosed asthma (OR: 1.79; 95% CI: 1.33–2.41, p < 0.0001), use of inhaled corticosteroids (OR: 1.78; 95%CI: 1.38–2.29, p < 0.0001), maternal tobacco smoking during pregnancy (OR:1.69; 95% CI: 1.19–2.39, p = 0.003) and onset of wheezing in the first trimester of life (OR: 1.30; 95% CI: 1.02–1.66, p = 0.038). Breast feeding ≥4 months (OR: 0.72; 95% CI: 0.54–0.96, p = 0.004), maternal high educational level (>12 years) (OR: 0.66; 95% CI: 0.51–0.85, p = 0.001) and total monthly household income ≥US$ 3,000 (OR: 0.34; 95% CI: 0.18–0.67, p = 0.002), were protective factors.Conclusions: Infants with recurrent asthma-like symptoms have a high rate of admissions. Tobacco smoking in pregnancy, viral respiratory illness in the first trimester of life and severe progression were risks for admissions. Improving medical management to prevent severe exacerbations, prolonging the postnatal period at home longer than 3 months, favouring breastfeeding and avoiding smoking during pregnancy may have a preventive role for admissions in infants with recurrent asthma-like symptoms.
Published: 2021
Full Text: View/download PDF

34. Development of a Tool to Measure the Clinical Response to Biologic Therapy in Uncontrolled Severe Asthma: The FEV1, Exacerbations, Oral Corticosteroids, Symptoms Score

Author: Javier Domínguez-Ortega, Iñigo Ojanguren, Gregorio Soto, José María Vega Chicote, Antonio Parra Arrondo, Miguel Perpiñá, Carolina Cisneros, Isabel Urrutia, Juan Luis García-Rivero, Eva Martínez-Moragón, Carlos Almonacid, Valentina Gutiérrez Vall De Cabrës, Irina Bobolea, Antolín López Viña, Marina Blanco, Dario Antolin, Astrid Crespo, Alfons Torrego, Joaquín Sastre Domínguez, Paloma Campo Mozo, Victoria García Gallardo, Vicente Plaza, Mar Mosteiro, Ismael García Moguel, Ignacio Dávila, Carlos Colás, Aythamy Henrquez Santana, Luis Pérez de Llano, Alicia Habernau Mena, Francisco Álvarez, Juan Carlos Miralles, Remedios Cardenas Contreras, Borja G. Cosío, Manuel Jorge Rial Prado, César Picado, Loreto Carmona, José María Olaguibel Rivera, Xavi Muñoz, Santiago Quirce Gancedo, Pilar Barranco Sanz, José Ramón Serrano, Ignacio Antepara Ercoreca, Julio Delgado Romero, Cristian Domingo, and María Jesús García de Yébenes
Subjects: medicine.medical_specialty, Potentially all pairwise rankings of all possible alternatives, business.industry, Maintenance dose, medicine.drug_class, Intraclass correlation, Minimal clinically important difference, Context (language use), medicine.disease, 03 medical and health sciences, 0302 clinical medicine, 030228 respiratory system, Internal medicine, medicine, Immunology and Allergy, Corticosteroid, 030212 general & internal medicine, business, Face validity, Asthma
Abstract: Background There is a lack of tools to quantify the response to monoclonal antibodies (mAbs) holistically in severe uncontrolled asthma patients. Objective To develop a valid score to assist specialists in this clinical context. Methods The score was developed in four subsequent phases: (1) elaboration of the theoretical model of the construct intended to be measured (response to mAbs); (2) definition and selection of items and measurement instruments by Delphi survey; (3) weight assignment of the selected items by multicriteria decision analysis using the Potentially All Pairwise RanKings of All Possible Alternatives methodology using the 1000minds software; and (4) face validity assessment of the obtained score. Results Four core items, with different levels of response for each, were selected: severe exacerbations, oral corticosteroid use, symptoms (evaluated by Asthma Control Test), and bronchial obstruction (assessed by FEV1 percent predicted). Severe exacerbations and oral corticosteroid maintenance dose were weighted most heavily (38% each), followed by symptoms (13%) and FEV1 (11%). Higher scores in the weighted system indicate a better response and the range of responses runs from 0 (worsening) to 100 (best possible response). Face validity was high (intraclass correlation coefficient of 0.86). Conclusions The FEV1, exacerbations, oral corticosteroids, symptoms score allows clinicians to quantify response in severe uncontrolled asthma patients who are being treated with mAbs.
Published: 2021
Full Text: View/download PDF

35. An independent inter- and intraobserver agreement assessment of the AOSpine sacral fracture classification system

Author: Manuel Valencia, Ratko Yurac, Julio Urrutia, Marcelo Valacco, Gaston Camino-Willhuber, Arturo Meissner-Haecker, and Nelson Astur
Subjects: Sacrum, Context (language use), Classification scheme, 03 medical and health sciences, 0302 clinical medicine, Cohen's kappa, Humans, Medicine, Orthopedics and Sports Medicine, In patient, Prospective Studies, Observer Variation, 030222 orthopedics, business.industry, Reproducibility of Results, Sacral fracture, Sagittal plane, medicine.anatomical_structure, Coronal plane, Spinal Fractures, Surgery, Neurology (clinical), business, Nuclear medicine, 030217 neurology & neurosurgery
Abstract: BACKGROUND CONTEXT The AOSpine sacral classification scheme was recently described. It demonstrated substantial interobserver and excellent intraobserver agreement in the study describing it; however, an independent assessment has not been performed. PURPOSE To perform an independent inter- and intraobserver agreement evaluation of the AOSpine sacral fracture classification system. STUDY DESIGN Agreement study. METHODS Complete computerized tomography (CT) scans, including axial images, with coronal and sagittal reconstructions of 80 patients with sacral fractures were selected and classified using the morphologic grading of the AOSpine sacral classification system by six evaluators (from three different countries). Neurological modifiers and case-specific modifiers were not assessed. After a four-week interval, the 80 cases were presented to the same raters in a random sequence for repeat assessment. We used the Kappa coefficient (κ) to establish the inter- and intraobserver agreement. RESULTS The interobserver agreement was substantial when considering the fracture severity types (A, B, or C), with κ=0.68 (0.63–0.72), but moderate when considering the subtypes: κ=0.52 (0.49–0.54). The intraobserver agreement was substantial considering the fracture types, with κ=0.69 (0.63–0.75), and considering subtypes, κ=0.61 (0.56–0.67). CONCLUSION The sacral classification system allows adequate interobserver agreement at the type level, but only moderate at the subtypes level. Future prospective studies should evaluate whether this classification system allows surgeons to decide the best treatment and to establish prognosis in patients with sacral fractures.
Published: 2021
Full Text: View/download PDF

36. Conocimiento de las iniciativas de adecuación de la práctica clínica en profesionales de hospital

Author: P. Tudela, G. Ezcurra, A. Urrutia, and C. Gaona
Subjects: business.industry, Medicine, General Medicine, business, Humanities
Published: 2022
Full Text: View/download PDF

37. Hospital health personnel’s knowledge of initiatives on the appropriateness of clinical practice

Author: A. Urrutia, G. Ezcurra, C. Gaona, and P. Tudela
Subjects: Clinical Practice, Health Knowledge, Attitudes, Practice, Health personnel, Nursing, business.industry, Health Personnel, Humans, Medicine, General Medicine, business, Hospitals
Published: 2022
Full Text: View/download PDF

38. BJS commission on surgery and perioperative care post-COVID-19

Author: E. Abahuje, A. Abbas, M. Abd El Aziz Abd El Maksoud, A. Abdelhady, S. Abdelhamid, H. Abdelkarem Ahmed Faraj, B. Abdelqader, T. Abdelrahman, H. Abdou, A. Abdullah, M. Abedua Harrison, E. Abem Owusu, A. Aboalazayem, R. Aboulhosn, S. Abu Oda, A. Abubakar, A. Abutaka, D. Acevedo Fontalvo, S. Acuna, A. Adefemi, S. Adegbola, T. Adenuga, A. Adeyeye, A. Adil Hilmi, A. Adisa, K. Aditya, T. Adjeso, R. Aftab, A. Afzal, V. Aggarwal, A. Aggarwal, R. Aguilera, M. -L. Aguilera-Are´valo, E. J. Aguirre Salamanca, I. Aguirre-Allende, D. Ahari, H. Ahmad, F. Ahmad Rauf, A. Ahmad Zartasht Khan, S. Ahmed, N. Ahmed Fieturi, S. Ahmed Mohamed, Z. Ahmed-Bakhsh, M. Ahsan Javed, L. Akano, A. Akbar, M. Akhbari, P. Akhmedov, G. Aksit, Y. Akula, A. S. Alagaratnam, S. Al Majid, O. Al Mukhtar, H. Al Omran, N. AlAsali, M. Al-Azzawi, R. Al-Habsi, H. Al-Iraqi, H. Al-Naggar, E. Alameer, H. Albirnawi, D. Alderson, F. Aldulaijan, R. Alejandro Miranda Ojeda, A. AlHasan, S. Ali, A. Ali, M. Ali Khan, Y. Alimova, F. Aljanadi, R. Aljubure, N. Allopi, H. Almedbal, M. Almubarak, Z. Alqaidoom, N. Alselaim, M. Alshaar, R. Alshammari, K. Altaf, S. Altıner, B. Altunpak, L. A. Alvarez Lozada, E. Amal Nahal, A. Amer, K. Amin, U. Aminu, N. Amisi Numbi, T. Amjad, R. Amoah, Y. An, N. -A. Anastasopoulos, J. Andre´s Urrutia, F. Angarita, K. -L. Angarita, M. A´ ngel FreirI´a Eiras, A. Antypas, M. A. Anwar, H. Anwar, T. O. Apampa, K. Apostolou, C. Aquina, R. Arachchige Adithi Himika Randeni, M. I. Archila Godı´nez, O. Arez, A. A. Arezzo, P. Armonis, S. Arshad, M. Arshad Salman, A. Arshid, P. C. Arteaga Asensio, T. Arthur, A. Arumuga Jothi, F. Aryo Damara, L. Asensio Gomez, J. Ashcroft, S. Ashraf, A. Asif, M. Atif, M. Attaullah Khan, N. Avellaneda, S. Awad, M. Awadh, A. Axiaq, A. Ayad Mohammed Shuwayyah, D. Ayalew, E. Aytac, F. Azam, J. Azevedo, B. Azhar, J. Aziz, A. Aziz, A. Azzam, A. Baba Ndajiwo, M. Baig, D. Baker, F. Bakko, R. Balachandran, G. Balachandran, J. Balagizi Mudekereza, E. Balai, B. Balci, A. Balduzzi, A. Balhareth, S. Bandyopadhyay, D. Banerjee, D. Bangalore Mahalinga, B. Bankhead-Kendall, N. D. A. Bankole, V. Banwell, F. Baris Bengur, B. Baris Ozmen, M. Barnard, R. Barnett, J. A. Barreras Espinoza, A. Barrios, G. Bass, M. Bass, A. Bausys, A. Bavikatte, J. Bayram, M. Belousov, A. G. Berardi, A. Beamish, C. Beattie, F. Belia, V. Bellato, S. Bellikatti, S. Benjamens, C. Benlice, S. Bennedsgaard, S. Bennett, Z. Bentounsi, H. Bergenfeldt, A. Bergenfelz, M. Besselink, G. Bhandoria, E. Bhangu, M. Bhatia, M. T. Bhatti, Z. Bilgili, G. Bislenghi, C. Bisset, S. Biswas, J. Blake, R. Blanco, L. Boccalatte, R. Boden, C. Bojanic, M. Boland, P. Boland, E. Bollen, E. -A. Bonci, L. Boni, A. Booth, R. Booth, A. Borakati, G. E. Borunda Escudero, S. J. Bosco, P. Bostro¨ m, P. Botelho de Alencar Ferreira Cruz, K. Bouchagier, A. Bouhuwaish, M. Boutros, K. Boyce, C. Boyle, L. Bradshaw, A. Brandl, A. Brar, G. Brat, H. Brenkman, C. Brennan, C. Brines, A. Brookmyre, C. Brosnan, L. Brouwers, A. Brown, L. Brown, C. Brown, J. Brown, V. BS, M. Buksh, M. Bunani Emmanuel, D. Burbano, A. Burelli, A. Burke, J. Burke, N. Burlov, A. Burns, O. Burton, A. Butt, B. Buzra Ozkan, L. Cabrera Silva, E. Y. Caicedo, T. Calderbank, W. Cambridge, G. Campelo, O. Can Tatar, F. Carbone, F. Carrano, D. Casallas, D. Casanova Portoles, F. Casciani, I. Cassimjee, O. A. Castaneda Ramı´rez, V. Catala´ n, J. Caviedes, L. Cayetano, M. ~ Ceresoli, M. Chan, V. Chan, P. Chandrasinghe, S. Chapman, A. Chaturvedi, D. Chaudhry, H. Chaudry, H. W. Chen, A. Cheng, M. Chernykh, A. M. Cherrie, I. Cheruiyot, J. Cheung, C. Chia, J. Chica, N. Chinai, A. Chirwa, J. Chiwaligo, A. Choi, J. Choi, M. R. Chowdhury, E. Christopher, N. Christou, T. Chu, D. Chua, H. W. Chua, C. Chung, A. Cihat Yildirim, M. Cillo, S. Cioffi, H. Claireaux, S. Clermonts, R. Clifford, M. Climent, A. Clynch, R. -J. Coelen, E. Cola´ s-Ruiz, A. Collar, M. Collard, K. C. Conlon, T. Connelly, K. Connor, J. A. Cook, T. Correia de Sa´, N. Cos¸gun Acar, T. Costa, D. Couch, S. Cowper, B. Creavin, B. Crook, A. Curell, R. D’alessio, J. Dale, J. Damgaard Eriksen, I. Dario Martin Gonzalez, A. Darwish, M. Das, R. Das, K. Das, R. Dave, S. O. David, T. Davies, C. Davis, S. Davison, V. Davletshina, A. Dawidziuk, A. Dawson, M. de Andres Crespo, H. de Berker, P. de Dieu Ngo, E. Dekker, R. de la Caridad Espinosa Luis, B. de Lacy, N. Demartines, A. de Montserrat Medina Sifuentes, S. De Silva, C. del Rio, V. Delaune, A. Dell, I. Demirbas¸, S. Demirli Atici, M. Deniz Tepe, M. Derebey, G. Desai, M. Desai, S. Devarakonda, N. Deveras, G. Di Franco, M. Di Martino, F. Di Marzo, A´ . Dı´az, G. Diaz del Gobbo, C. DiazCastrillon, L. Dick, K. Dickinson, E. Diego, I. Dimasi, A. Ding, S. Dingemans, L. Dixon, B. Dixon, W. Doherty, D. Dooreemeah, C. Donohue, M. Dornseifer, F. Dossa, W. Dossou, T. Drake, I. Drami, G. Drevin, M. C. du Plessis, N. Dudi-Venkata, R. Dudley, S. Duffy, D. Duklas, B. -D. Dumbrava, F. Duygu Avlar, A. Dworzynska, W. Ebrahim, A. Ebrahim, E. Efre´n Lozada Herna´ ndez, N. Ehigie, M. El Boghdady, C. El Hasnaoui, M. El Sheikh, A. El-Hussuna, O. Eldurssi, H. Elfeki, M. Elhadi, M. Elhassan, A. Elhissi, B. Elliot, C. Elsenbroek, B. Elsolh, N. Elson, H. Eltyeb, H. Emerson, S. H. Emile, G. Endalle, W. English, C. Ercisli, G. Espinosa, M. Essam Abdelraheem, H. Essangri, P. Etienne, M. D. Evans, T. Evans, C. Ezeme, F. Ezzahraa, T. Fadalla, J. Fagan, M. Fahmy, C. Fairfield, O. Falade, S. Famularo, F. Faqar-Uz-Zaman, Y. Farid, A. Farooq, H. Farooq, F. Farooqui, B. Farquharson, A. Faruqi, R. Faulder, M. Faut, K. Fechner, T. Feenstra, M. Fehervari, L. Fernandez, J. Ferna´ ndez Alberti, L. Ferrario, D. Field, L. Fiore, S. Fingerhut, S. Finlayson, N. Fleming, C. Fleming, E. Florial, M. Fok, D. Fokin, M. Foley, M. P. Forero, T. Forgan, M. Fornasiero, H. Fowler, G. Fowler, E. Franchi, L. Franklin, A˚ . Fredriksson, P. Fruhling, G. Fuentes Navarrette, A. Fu¨ lo¨ p, M. Furtado, T. Gaarder, N. Galbraith, I. T. K. Gallagher, G. Gallo, T. Gana, E. Gaskin, M. Gasparini, R. G. Gatan, E. Geary, K. Gelaye Wudineh, G. Gemenetzis, M. Georgi, H. Ghalige, W. Ghareeb, T. Ghatwary Tantawy, C. Ghomsi, A. Ghuman, P. Giannakis, F. Giron, K. Gjengedal, E. Gkotsis, J. Glasbey, S. Godahewa, D. Godula, P. Goffredo, S. Goh, M. Golriz, L. Gomez, D. Gomez Gomez, R. Gonzalez, D. Gonzalez, E. Gonzalez Gutierrez, D. Gopar, L. Gordini, A. Gori, S. Gorta´ zar, N. Gousy, R. Gowda, M. Gowda, J. Gqada, M. Grechenig, J. Greer, L. Grego´ rio, A. Grigorova, H. Grimes, V. Groot, R. C. Grossman, R. Gruber, A. Gru¨ ter, R. Guest, R. Gujjuri, E. Gu¨ lc¸ek, B. Gulcu, K. Gull, M. Gulmez, V. Gupta, A. Gutlic, T. Guven, T. Gwatirisa, G. Gwini, P. Gwodog, S. Gysling, M. Habib, A. B. Hafeez Bhatti, J. Hallesmith, S. Halloran, M. Hamza Sadiq, C. Haney, N. Hanna, L. Hanna, M. Hannington, J. Harbjerg, D. Haribaskaran, N. Harran, B. Harrington, E. Harrison, R. Hasan, S. Hashmi, M. Hassan, A. Hassan, L. Haverkamp, S. Hazen, B. Heer, J. Heil, J. Helliwell, N. Henriksen, D. Henshall, M. Hermanson, S. Hermena, D. Hettiarachchi, C. Hextall, M. Hidalgo, H. Hidayat, A. Hider, P. Higgins, R. Hinchliffe, D. Hirani, D. Hirpara, I. Hisham, M. Hite, S. M. Hoh, C. Holmberg, E. Ho¨ lmich, F. Holst, A. Hossam, A. Hossam Elfallal, P. Howard, E. Huaman, Y. Huang, L. Huang, D. Huang, T. Huber, J. Hugh, J. Hughes, F. Hu¨ ttner, R. Huynh, A. Hylands, J. Iannuzzi, B. Ielpo, A. Iftikhar Talib, J. Ignacio, P. Ignatavicius, S. Ike, C. Ikwu, M. Inama, A. Ing, A. Ingels, A. Isik, N. Islam, I. J. Ives, A. J. M. S. AlHasan, C. J. Perez Rivera, F. Ja´ come, T. Jaffer, O. Jagiella-Lodise, M. Jain, K. Jain, M. Jakubauskas, M. Jalal, H. James, Y. Jang, B. Janssen, H. Jansson, U´ . Jariod-Ferrer, H. Javanmard, S. Javed, U. Jayarajah, I. Jayasuriya, J. Je, Z. Jessop, E. Jia Lin Tang, H. Jiang, Y. Jiayan, T. Jih Huei, R. Jimenez-Rodriguez, D. Joh, A. Johnson, N. Jones, C. Jones, C. Jordan, J. Jose´ Nu´ nez Ju, ~ M. Jose´ Pizarro, C. Jose Salazar J. Joseph, C. Justiniano, T. Kabir, M. Kadhum, C. Kalfountzos, E. Kalogiannaki, K. Kalyanasundaram, S. Kamarajah, M. Kamil Quraishi, Y. Kanemitsu, A. Kapila, V. Kapila, G. Karagiannidis, M. Kashif, S. Kathiravelupillai, A. Kathiravelupillai, E. Katsogridakis, K. Kaur, H. Kaur Sekhon Inderjit Singh, N. Kausur, M. Kawka, G. Keehan, S. Kehlet Watt, M. Kelly, M. E. Kelly, I. Kelvin Egbuchulem, G. Kembuan, E. Khajeh, A. Khaled Elfaitur, M. F. Khan, S. Khan, M. Khan, D. Khan, H. Khan, H. Khatkar, E. Khatkov, R. Khaw, B. Kim, K. Kishore Siddiraju, D. Kitua, B. Kırımtay, S. Kmezic, S. Knight, T. Koe¨ter, A. Koh, F. Koh Hong Xiang, T. Kojo Anyomih, A. I. N. Kok, R. Kokelaar, I. Koliarakis, S. Kolli, J. Kong, D. Ko¨ nig, M. otze, A. Kourdouli, M. Kowal, A. Kraima, F. Kramer, M. Kryzauskas, I. Kuchynskyi, C. Kuemmerli, S. Kuiper, S. Kumar, A. Kumar, L. Kumar, H. Kumar, N. Kumar, S. Kumar Bandyopadhyay, P. Kumar Garg, S. Kumar Venkatappa, J. Kung, S. Kural, A. Kushairi, E. Kuuzie, M. Kvietkauskas, I. Kwek, J. La, L. Lai, S. Lakpriya, K. Lam, M. Lami, I. Lansdorp-Vogelaar, P. Lapolla, H. Larsen, J. Latif, U. Laudari, A. Laurnezi, A. Lawal, S. Lawday, H. Lederhuber, A. Lednev, R. Lee, M. E. van Leerdam, G. Lefevbre, M. Lesmus, F. A. Leyva Moraga, E. Leyva Moraga, F. Leyva Moraga, H. L. Li, A. Li, Z. Li, E. Licardie, A. Light, A. L. Lightner, A. Lin, E. Lincango, F. Litta, H. Liu, B. Lofthouse, M. A. Londono, R. Lopes, R. Lopes de Freitas, L. Lopez, A. I. Lo´ pez, J. ~ Lopez-Gomez, G. Lopez-Pena, R. Lowe, D. Lowe, M. Lowey, G. Loy, V. Lozanovski, J. Luzon, P. Lynn, T. Maccabe, A. Machielsen, C. A. Mafla Herrerı´a, L. Maggino, K. Mahawar, D. Mahmood, M. Mahmoud, K. Mahtani, I. Maitra, S. Maji, I. Majiet, L. Mal, J. Malherbe, K. Malhotra, P. Malkomes, E. Man, A. Manan Sheikh, S. Manjunath, R. Manzano Nunez, S. Manzoor, R. Maqsood, G. ~ Marchegiani, F. Marchegiani, D. Marı´n, A. Marin, I. Marks, E. Marson, A. Martensen, D. Martin, G. Martı´n Martı´n, B. Martin-Perez, P. Martinez, P. Marwaha, C. Mashauri, H. Mashbari, Ł. Masior, R. Masri, L. Masud, S. Masudi, G. Mateu Calabuig, S. Math, A. Matrachisia, J. Mayol, D. Mazingi, A. Mazzotta, J. McAlinden, G. McCabe, L. McColm, H. McElvaney, K. McGivern, J. McGovern, E. McGuinness, N. McInerney, S. Mckay, C. McKee, M. McKenna, N. McKenna, K. McLean, S. Mediratta, Y. Medkova, O. Medzhidov, A. Mehraj, M. Mekhael, O. Mekinde, C. Mellenthin, A. Melucci, K. Mentor, J. Merchant, H. Messias, M. Messeha, C. Meza, P. Mhango, M. Miladinov, M. Milagros Niquen Jimenez, P. Miller, E. Mills, A. Milton, O. A. Minayeva, Z. MinHua Zheng, H. Mischlinger, B. Mo¨ ckli, R. Modi, H. M. Mohamed, M. Mohamed, T. Mohamed Abulghasm, S. A. Mohammad, T. O. Mohammed, A. Mohammed, H. Mohan, M. Mohan, I. Moin, V. Mok, G. Molina, J. Moloney, J. Moneim, M. Monfort Mira, B. Montcusı´ Ventura, M. Montouri, M. Moossdorff, I. Mora-Guzma´ n, B. Moran, R. A. R. Mora´ n, S. Moreno-Ordaz, A´ . Morera, R. Morgan, R. Morley, D. Moro-Valdezate, S. Moros, J. -L. Moss, A. Morven, D. Morton, A. Moynihan, M. Moyo´ n, N. Muduli, N. Mugla, W. Mugla, P. Mu¨ ller, G. Mun, R. Mundhada, I. Munir, F. Munoz, E. Mu ~ noz, A. Mu ~ noz, D. ~ C. Munoz Balderas, E. Murgitroyd, V. Murray, S. Murthy, W. ~ Mushiwokufa, H. Mustafa, B. Mustakimov, P. Mutambanengwe, P. Myint, S. Nadkarni, P. A. Naess, S. Nahar, P. Naidoo, R. Nam, S. Nandhra, N. Nanjappa, V. Narasimhan, W. Nardi, M. Nasir, A. Naughton, D. Naumann, S. Navarro, M. Nawaaz Karimbocus, A. Nazir, S. Ndereya, A. Ndong, I. Negoi, D. Nel, D. Nelson, S. Nepal, T. Nugent, D. Nepogodiev, J. Neufeld, J. Ng, D. Ng, C. E. Ng, S. Ngaserin, L. Ngu, E. Ngwenya, R. N. Fhearaigh, T. -K. Nikolousakis, M. Ninkovic, G. Nita, C. Nitschke, E. Noren, T. Noton, A. Novikova, Z. Nowinka, T. Nyakunengwa, A. Nyalundja, I. Nzenwa, H. Ø Kristensen, C. O’Brien, L. O’Brien, S. O’Brien, J. O’Reilly, S. O’Rourke, M. O’Sullivan, M. O’Dwyer, L. Ochieng, E. Oderoha, K. E. Oh, L. O¨ hlberger, M. O¨ lc¸u¨ m, A. Olkina, M. Omkumar, B. Omnitel, D. Oncel Yakar, K. Ong, L. Ong Wei Lin, R. Ooi, S. Ooi, A. Oomman, D. Oon Tyjet, S. Opiyo, J. J. Oscullo Yepez, N. Osei-kuffour, T. Osunronbi, A. Ottlaka´ n, S. Oussama Kacimi, S. Ovaere, A. Ozair, F. Pachler, S. Pai Oo, S. Paiella, L. Panaiotti, N. Panda, S. Pandarinath, D. Pandey, S. Pandrowala, F. Papa Mamadou, M. Paranathala, J. Park, C. Parmar, A. Parvez, L. Pasovic, A. Pasquer, N. Pasumarthy, F. Pata, T. Patel, P. Patel, N. Patel, M. Patel, N. Patron Uriburu, R. Patrone, A. Paul, O. M. Pavan Kumar, A. Pavithran, M. Pedraza Ciro, G. Pellino, A. Peloso, M. T. Pena~ Gallardo, A. Pena Velazquez, J. Perea, L. E. Pe´rez-Sa´ nchez, T. ~ Perra, G. Perrotta, P. Petersson, G. Petra, N. Petrucciani, C. Pickin, V. Pino, E. Pinotti, F. Pinto, P. Plum, F. Podesta, T. Pollini, M. Pompeu Sa´, F. Ponce Leon, H. S. Ponniah, X. Ponte de Sousa, J. Ponton, A. Pontula, M. Popa, A. L. Portilla, F. Posner, S. Post, A. Potolicchio, S. Pouwels, A. Povo, P. Prasad, S. Preciado, R. Preece, D. Proud, J. A. Pulido Segura, N. Puliyath, M. Qui, A. S. Quimbaya Rodrı´guez, W. Raby-Smith, A. Racovit¸a, A. Rad, R. Radwan, M. Rafaih Iqbal, A. Rafik, B. Raguan, M. Rahi, J. -L. Rahiri, J. Rahme, L. Rai, A. Raj, A. Raj Saksena, M. Raja, J. Ramirez, J. Ramzi, J. Ranstam, C. Rao, A. Rashid, B. Ratnayake, K. Rattanasirivilai, K. Raubenheimer, N. Ravikumar, S. Ravn, N. Razoz, W. Rea, A. Regan, M. Rela, A. Remme, C. E. Rey Chaves, A. Reyes, A. Riad, D. Rice, K. Rios Quintana, A. Ritter, M. Roalsø, D. Robinson, J. Rodriguez, F. Rodrı´guez, M. C. Rodriguez, A. Rogers, J. Rohila, D. Romanyuc, I. Romic, M. Rommaneh, G. Rompianesi, F. Rosa, F. Roscio, A. Rose, T. Rotimi, H. Ruiz, J. Ruiz Yucuma, E. Ruiz-U´ car, M. Ruslan, M. Rutega˚ rd, E. Ryan Harper, A. Ryckx, D. Rydbeck, E. Fonseca, A. Sanchez Teran, S. Sanchez Ussa, O. Sandli, H. Sanfey, J. Sanghera, I. Sani, M. Santafe Guerrero, M. Sante Fornasiero, O. Santes Jasso, I. Santos Pereira, H. Santos Sousa, A. Saratzis, A. Sarmiento Alarcon, T. Saumtally, R. Sayyed, M. Schettino, L. Schleimer, T. Schmidt, K. Schondffelt, M. Schwab, A. Scott, H. Searle, L. Sebopelo, B. Seeglier, R. Seishima, D. Semenvov, A. Senent-Boza, J. Sepulveda, M. Serenari, M. Serrano Navidad, I. Sert, E. Sewart, A. Sgro`, V. Shadrina, K. Shah, F. Shahid, M. Shalaby, B. Shankar, J. Shapiro, L. Sharma, A. Sheel, A. Shenfine, S. Shenoy, A. Sherif, N. Shetty, R. Shetty, T. C. Sia, D. Sichimba, H. Siddique, I. Siddiqui, G. Simkens, J. Simoe, H. Simon, L. Sinan, T. Singh, K. Singh, Y. Singh, L. Sinha, L. Siragusa, T. Sluckin, Y. W. Smart, H. Smith, K. Smith, L. Smits, C. Sneep-van Kessel, C. Sohrabi, O. Solo´ rzano Pineda, A. Soma, L. Sooriyapiragasam, K. Søreide, M. Sparavigna, R. Spence, N. Spencer, H. Spiers, A. Spinelli, J. Sprakel, S. Sravanam, M. Srinivasan, R. Srinivasan, A. Staniszewska, S. J. Stanworth, K. Stasinos, R. J. C. Steele, I. Steinholt, M. Steinruecke, B. -J. Stephen, J. Stijns, M. Still, W. Stupalkowska, S. Subba, V. V. Subbotin, P. Sucharitkul, A. Sudarsanam, D. Sudhamsh Reddy, T. Suhardja, M. Suliman, M. Sund, A. Sunilkumar, N. Suresh, S. Sussmes, P. Sutton, J. Syltern, A. Taha, Y. Takamizawa, A. B. Takoutsing Dongmo, T. Tama´ s, L. Tan, J. L. Tan, K. Tan, E. Tan, A. Tan Yong Hui, A. Tanase, A. Tariverdiev, A. Tasnem, C. Tatar, E. Tay, P. Tejedor, G. Tesfaye, F. Tetinou, C. Thorpe, A. Thyø, D. Tlelo Amastal, M. Tolani, K. Tolga Saracoglu, T. To¨ lgyes, J. Tong, L. Torrent Jansa`, S. Toscano Igartua, M. R. Tovani Palone, H. Traff, J. Trevis, W. Tummers, A. Tur, I. Turchenko, V. Uche, A. Uddin, N. Udonsak, M. Ullah, T. Urbonas, C. Uwins, E. Uy Magadia, A. Uzair Qureshi, K. Uzun, P. Vadim, G. Valarche, R. A. Valdez Gonzalez, M. Vallee, D. -J. van Beek, A. S. van Dalen, D. van den Hondel, E. van der stok, M. van Dorp, S. van Oostendorp, E. van Praag, J. van Rees, L. van Silfhout, Z. Varga, S. Varghese, C. Varghese, J. Varghese, A. -M. Vasilica, X. Va´ squez Ojeda, E. Vega, S. Vehler, R. Venchiarutti, S. Vengatesan, M. Venn, D. Verma, G. Vianey Partida Nava, D. Victoria, P. Vieira, M. E. Vilar Alvarez, D. Vinci, G. Viscasillas Palla` s, M. Viswanath, J. Vivanco, V. Vizcaya Rodrı´guez, J. Vo, D. Volchanski, T. Voron, Y. Voronovskyi, J. Vu, M. Wadhwa, S. Wadhwa, G. Wagner, M. Wallace, Y. Y. Wang, J. Wang, A. Wani, K. Wanigasooriya, S. Wanjara, N. Wanjiku, C. Warner, T. Wei Leow, T. Weiser, M. Weisters, M. J. Wellington, C. Wells, C. Wenzelberg, D. Wettstein, A. Wezel, L. Wheldon, L. Widmer, M. Wilson, S. Wigmore, T. Wijayaratne, M. Wijeyaratne, B. P. L. 1176 | BJS, 2021, Vol. 108, No. 10 Sá-Marta, I. Sadien, D. SafariNteranya, K. Sagoo, S. Sakata, E. Saladino, A. Saleem, S. Saleem, M. Salehi, S. Salih, V. Sallinen, S. Salvans, Z. H. Sam, E. Samadov, M. Sampaio Alves, A. Sanad, S. Sánchez Wijnhoven, R. Wilkin, E. Williams, F. Willis, D. Winter, M. M. Wirsik, B. Wishah, G. Wong, W. J. Wong, K. Wong, K. -Y. Wong, D. Worku, E. Wright, J. Wright, O. Wroe Wright, S. Xenacki, W. Xia, W. Xu, Z. Xu, A. Yalcinkaya, W. Yang, P. -C. Yang, A. Yanishev, A. Yanzon de la Torre, H. Yao, E. Yaqoob, S. Yen Ling Quake, D. Yeo, B. Yeom, D. Yershov, M. Yiasemidou, A. Yildiz, A. Yiu, M. Yoav, E. Yong, R. Yoshimura, M. U. Younis, Z. Younis Ringshawl, M. Youssef, Y. Yue, S. Yuen, R. Yuldashev, C. Yurttas, B. Yves, A. Zaborowski, R. Zackeri, A. Zafar, W. Zahra, A. Zaidi, S. Zainudin, R. Zakeri, I. Zamora, A. T. Zamora, M. Zawistowski, G. Zbikowska, W. Zegers, S. Zehra, A. Zeyra, Z. Zhagniyev, L. G. Zhukova, M. Zivanovic, J. Zmuc, M. Zope, A. Zubayraeva, B. Zucker., Abahuje, E., Abbas, A., Abd El Aziz Abd El Maksoud, M., Abdelhady, A., Abdelhamid, S., Abdelkarem Ahmed Faraj, H., Abdelqader, B., Abdelrahman, T., Abdou, H., Abdullah, A., Abedua Harrison, M., Abem Owusu, E., Aboalazayem, A., Aboulhosn, R., Abu Oda, S., Abubakar, A., Abutaka, A., Acevedo Fontalvo, D., Acuna, S., Adefemi, A., Adegbola, S., Adenuga, T., Adeyeye, A., Adil Hilmi, A., K. Aditya, A. Adisa, Adjeso, T., Aftab, R., Afzal, A., Aggarwal, V., Aggarwal, A., Aguilera, R., Aguilera-Are´valo, M. -L., Aguirre Salamanca, E. J., Aguirre-Allende, I., Ahari, D., Ahmad, H., Ahmad Rauf, F., Ahmad Zartasht Khan, A., Ahmed, S., Ahmed Fieturi, N., Ahmed Mohamed, S., Ahmed-Bakhsh, Z., Ahsan Javed, M., Akano, L., Akbar, A., Akhbari, M., Akhmedov, P., Aksit, G., Akula, Y., Alagaratnam, A. S., Al Majid, S., Al Mukhtar, O., Al Omran, H., Alasali, N., Al-Azzawi, M., Al-Habsi, R., Al-Iraqi, H., Al-Naggar, H., Alameer, E., Albirnawi, H., Alderson, D., Aldulaijan, F., Alejandro Miranda Ojeda, R., Alhasan, A., Ali, S., Ali, A., Ali Khan, M., Alimova, Y., Aljanadi, F., Aljubure, R., Allopi, N., Almedbal, H., Almubarak, M., Alqaidoom, Z., Alselaim, N., Alshaar, M., Alshammari, R., Altaf, K., Altıner, S., Altunpak, B., Alvarez Lozada, L. A., Amal Nahal, E., Amer, A., Amin, K., Aminu, U., Amisi Numbi, N., Amjad, T., Amoah, R., An, Y., Anastasopoulos, N. -A., Andre´s Urrutia, J., Angarita, F., Angarita, K. -L., A´ ngel FreirI´a Eiras, M., Antypas, A., Anwar, M. A., Anwar, H., Apampa, T. O., Apostolou, K., Aquina, C., Arachchige Adithi Himika Randeni, R., Archila Godı´nez, M. I., Arez, O., Arezzo, A. A., Armonis, P., Arshad, S., Arshad Salman, M., Arshid, A., Arteaga Asensio, P. C., Arthur, T., Arumuga Jothi, A., Aryo Damara, F., Asensio Gomez, L., Ashcroft, J., Ashraf, S., Asif, A., Atif, M., Attaullah Khan, M., Avellaneda, N., Awad, S., Awadh, M., Axiaq, A., Ayad Mohammed Shuwayyah, A., Ayalew, D., Aytac, E., Azam, F., Azevedo, J., Azhar, B., Aziz, J., Aziz, A., Azzam, A., Baba Ndajiwo, A., Baig, M., Baker, D., Bakko, F., Balachandran, R., Balachandran, G., Balagizi Mudekereza, J., Balai, E., Balci, B., Balduzzi, A., Balhareth, A., Bandyopadhyay, S., Banerjee, D., Bangalore Mahalinga, D., Bankhead-Kendall, B., Bankole, N. D. A., Banwell, V., Baris Bengur, F., Baris Ozmen, B., Barnard, M., Barnett, R., Barreras Espinoza, J. A., Barrios, A., Bass, G., Bass, M., Bausys, A., Bavikatte, A., Bayram, J., Belousov, M., Berardi, A. G., Beamish, A., Beattie, C., Belia, F., Bellato, V., Bellikatti, S., Benjamens, S., Benlice, C., Bennedsgaard, S., Bennett, S., Bentounsi, Z., Bergenfeldt, H., Bergenfelz, A., Besselink, M., Bhandoria, G., Bhangu, E., Bhatia, M., Bhatti, M. T., Bilgili, Z., Bislenghi, G., Bisset, C., Biswas, S., Blake, J., Blanco, R., Boccalatte, L., Boden, R., Bojanic, C., Boland, M., Boland, P., Bollen, E., Bonci, E. -A., Boni, L., Booth, A., Booth, R., Borakati, A., Borunda Escudero, G. E., Bosco, S. J., Bostro¨ m, P., Botelho de Alencar Ferreira Cruz, P., Bouchagier, K., Bouhuwaish, A., Boutros, M., Boyce, K., Boyle, C., Bradshaw, L., Brandl, A., Brar, A., Brat, G., Brenkman, H., Brennan, C., Brines, C., Brookmyre, A., Brosnan, C., Brouwers, L., Brown, A., Brown, L., Brown, C., Brown, J., Bs, V., Buksh, M., Bunani Emmanuel, M., Burbano, D., Burelli, A., Burke, A., Burke, J., Burlov, N., Burns, A., Burton, O., Butt, A., Buzra Ozkan, B., Cabrera Silva, L., Caicedo, E. Y., Calderbank, T., Cambridge, W., Campelo, G., Can Tatar, O., Carbone, F., Carrano, F., Casallas, D., Casanova Portoles, D., Casciani, F., Cassimjee, I., Castaneda Ramı´rez, O. A., Catala´ n, V., Caviedes, J., Cayetano, L., ~ Ceresoli, M., Chan, M., Chan, V., Chandrasinghe, P., Chapman, S., Chaturvedi, A., Chaudhry, D., Chaudry, H., Chen, H. W., Cheng, A., Chernykh, M., Cherrie, A. M., Cheruiyot, I., Cheung, J., Chia, C., Chica, J., Chinai, N., Chirwa, A., Chiwaligo, J., Choi, A., Choi, J., Chowdhury, M. R., Christopher, E., Christou, N., Chu, T., Chua, D., Chua, H. W., Chung, C., Cihat Yildirim, A., Cillo, M., Cioffi, S., Claireaux, H., Clermonts, S., Clifford, R., Climent, M., Clynch, A., Coelen, R. -J., Cola´ s-Ruiz, E., Collar, A., Collard, M., Conlon, K. C., Connelly, T., Connor, K., Cook, J. A., Correia de Sa´, T., Cos¸gun Acar, N., Costa, T., Couch, D., Cowper, S., Creavin, B., Crook, B., Curell, A., D’Alessio, R., Dale, J., Damgaard Eriksen, J., Dario Martin Gonzalez, I., Darwish, A., Das, M., Das, R., Das, K., Dave, R., David, S. O., Davies, T., Davis, C., Davison, S., Davletshina, V., Dawidziuk, A., Dawson, A., de Andres Crespo, M., de Berker, H., de Dieu Ngo, P., Dekker, E., de la Caridad Espinosa Luis, R., de Lacy, B., Demartines, N., de Montserrat Medina Sifuentes, A., De Silva, S., del Rio, C., Delaune, V., Dell, A., Demirbas¸, I., Demirli Atici, S., Deniz Tepe, M., Derebey, M., Desai, G., Desai, M., Devarakonda, S., Deveras, N., Di Franco, G., Di Martino, M., Di Marzo, F., Dı´az, A´., Diaz del Gobbo, G., Diazcastrillon, C., Dick, L., Dickinson, K., Diego, E., Dimasi, I., Ding, A., Dingemans, S., Dixon, L., Dixon, B., Doherty, W., Dooreemeah, D., Donohue, C., Dornseifer, M., Dossa, F., Dossou, W., Drake, T., Drami, I., Drevin, G., du Plessis, M. C., Dudi-Venkata, N., Dudley, R., Duffy, S., Duklas, D., Dumbrava, B. -D., Duygu Avlar, F., Dworzynska, A., Ebrahim, W., Ebrahim, A., Efre´n Lozada Herna´ ndez, E., Ehigie, N., El Boghdady, M., El Hasnaoui, C., El Sheikh, M., El-Hussuna, A., Eldurssi, O., Elfeki, H., Elhadi, M., Elhassan, M., Elhissi, A., Elliot, B., Elsenbroek, C., Elsolh, B., Elson, N., Eltyeb, H., Emerson, H., Emile, S. H., Endalle, G., English, W., Ercisli, C., Espinosa, G., Essam Abdelraheem, M., Essangri, H., Etienne, P., Evans, M. D., Evans, T., Ezeme, C., Ezzahraa, F., Fadalla, T., Fagan, J., Fahmy, M., Fairfield, C., Falade, O., Famularo, S., Faqar-Uz-Zaman, F., Farid, Y., Farooq, A., Farooq, H., Farooqui, F., Farquharson, B., Faruqi, A., Faulder, R., Faut, M., Fechner, K., Feenstra, T., Fehervari, M., Fernandez, L., Ferna´ ndez Alberti, J., Ferrario, L., Field, D., Fiore, L., Fingerhut, S., Finlayson, S., Fleming, N., Fleming, C., Florial, E., Fok, M., Fokin, D., Foley, M., Forero, M. P., Forgan, T., Fornasiero, M., Fowler, H., Fowler, G., Franchi, E., Franklin, L., Fredriksson, A˚., Fruhling, P., Fuentes Navarrette, G., Fu¨ lo¨ p, A., Furtado, M., Gaarder, T., Galbraith, N., Gallagher, I. T. K., Gallo, G., Gana, T., Gaskin, E., Gasparini, M., Gatan, R. G., Geary, E., Gelaye Wudineh, K., Gemenetzis, G., Georgi, M., Ghalige, H., Ghareeb, W., Ghatwary Tantawy, T., Ghomsi, C., Ghuman, A., Giannakis, P., Giron, F., Gjengedal, K., Gkotsis, E., Glasbey, J., Godahewa, S., Godula, D., Goffredo, P., Goh, S., Golriz, M., Gomez, L., Gomez Gomez, D., Gonzalez, R., Gonzalez, D., Gonzalez Gutierrez, E., Gopar, D., Gordini, L., Gori, A., Gorta´ zar, S., Gousy, N., Gowda, R., Gowda, M., Gqada, J., Grechenig, M., Greer, J., Grego´ rio, L., Grigorova, A., Grimes, H., Groot, V., Grossman, R. C., Gruber, R., Gru¨ ter, A., Guest, R., Gujjuri, R., Gu¨ lc¸ek, E., Gulcu, B., Gull, K., Gulmez, M., Gupta, V., Gutlic, A., Guven, T., Gwatirisa, T., Gwini, G., Gwodog, P., Gysling, S., Habib, M., Hafeez Bhatti, A. B., Hallesmith, J., Halloran, S., Hamza Sadiq, M., Haney, C., Hanna, N., Hanna, L., Hannington, M., Harbjerg, J., Haribaskaran, D., Harran, N., Harrington, B., Harrison, E., Hasan, R., Hashmi, S., Hassan, M., Hassan, A., Haverkamp, L., Hazen, S., Heer, B., Heil, J., Helliwell, J., Henriksen, N., Henshall, D., Hermanson, M., Hermena, S., Hettiarachchi, D., Hextall, C., Hidalgo, M., Hidayat, H., Hider, A., Higgins, P., Hinchliffe, R., Hirani, D., Hirpara, D., Hisham, I., Hite, M., Hoh, S. M., Holmberg, C., Ho¨ lmich, E., Holst, F., Hossam, A., Hossam Elfallal, A., Howard, P., Huaman, E., Huang, Y., Huang, L., Huang, D., Huber, T., Hugh, J., Hughes, J., Hu¨ ttner, F., Huynh, R., Hylands, A., Iannuzzi, J., Ielpo, B., Iftikhar Talib, A., Ignacio, J., Ignatavicius, P., Ike, S., Ikwu, C., Inama, M., Ing, A., Ingels, A., Isik, A., Islam, N., Ives, I. J., Alhasan, A. J. M. S., Perez Rivera, C. J., Ja´ come, F., Jaffer, T., Jagiella-Lodise, O., Jain, M., Jain, K., Jakubauskas, M., Jalal, M., James, H., Jang, Y., Janssen, B., Jansson, H., Jariod-Ferrer, U´., Javanmard, H., Javed, S., Jayarajah, U., Jayasuriya, I., Je, J., Jessop, Z., Jia Lin Tang, E., Jiang, H., Jiayan, Y., Jih Huei, T., Jimenez-Rodriguez, R., Joh, D., Johnson, A., Jones, N., Jones, C., Jordan, C., Jose´ Nu´ nez Ju, J., Jose´ Pizarro, ~ M., Joseph, C. Jose Salazar J., Justiniano, C., Kabir, T., Kadhum, M., Kalfountzos, C., Kalogiannaki, E., Kalyanasundaram, K., Kamarajah, S., Kamil Quraishi, M., Kanemitsu, Y., Kapila, A., Kapila, V., Karagiannidis, G., Kashif, M., Kathiravelupillai, S., Kathiravelupillai, A., Katsogridakis, E., Kaur, K., Kaur Sekhon Inderjit Singh, H., Kausur, N., Kawka, M., Keehan, G., Kehlet Watt, S., Kelly, M., Kelly, M. E., Kelvin Egbuchulem, I., Kembuan, G., Khajeh, E., Khaled Elfaitur, A., Khan, M. F., Khan, S., Khan, M., Khan, D., Khan, H., Khatkar, H., Khatkov, E., Khaw, R., Kim, B., Kishore Siddiraju, K., Kitua, D., Kırımtay, B., Kmezic, S., Knight, S., Koe¨ter, T., Koh, A., Koh Hong Xiang, F., Kojo Anyomih, T., Kok, A. I. N., Kokelaar, R., Koliarakis, I., Kolli, S., Kong, J., Ko¨ nig, D., Otze, M., Kourdouli, A., Kowal, M., Kraima, A., Kramer, F., Kryzauskas, M., Kuchynskyi, I., Kuemmerli, C., Kuiper, S., Kumar, S., Kumar, A., Kumar, L., Kumar, H., Kumar, N., Kumar Bandyopadhyay, S., Kumar Garg, P., Kumar Venkatappa, S., Kung, J., Kural, S., Kushairi, A., Kuuzie, E., Kvietkauskas, M., Kwek, I., La, J., Lai, L., Lakpriya, S., Lam, K., Lami, M., Lansdorp-Vogelaar, I., Lapolla, P., Larsen, H., Latif, J., Laudari, U., Laurnezi, A., Lawal, A., Lawday, S., Lederhuber, H., Lednev, A., Lee, R., van Leerdam, M. E., Lefevbre, G., Lesmus, M., Leyva Moraga, F. A., Leyva Moraga, E., Leyva Moraga, F., Li, H. L., Li, A., Li, Z., Licardie, E., Light, A., Lightner, A. L., Lin, A., Lincango, E., Litta, F., Liu, H., Lofthouse, B., Londono, M. A., Lopes, R., Lopes de Freitas, R., Lopez, L., Lo´ pez, A. I., ~ Lopez-Gomez, J., Lopez-Pena, G., Lowe, R., Lowe, D., Lowey, M., Loy, G., Lozanovski, V., Luzon, J., Lynn, P., Maccabe, T., Machielsen, A., Mafla Herrerı´a, C. A., Maggino, L., Mahawar, K., Mahmood, D., Mahmoud, M., Mahtani, K., Maitra, I., Maji, S., Majiet, I., Mal, L., Malherbe, J., Malhotra, K., Malkomes, P., Man, E., Manan Sheikh, A., Manjunath, S., Manzano Nunez, R., Manzoor, S., Maqsood, R., ~ Marchegiani, G., Marchegiani, F., Marı´n, D., Marin, A., Marks, I., Marson, E., Martensen, A., Martin, D., Martı´n Martı´n, G., Martin-Perez, B., Martinez, P., Marwaha, P., Mashauri, C., Mashbari, H., Masior, Ł., Masri, R., Masud, L., Masudi, S., Mateu Calabuig, G., Math, S., Matrachisia, A., Mayol, J., Mazingi, D., Mazzotta, A., Mcalinden, J., Mccabe, G., Mccolm, L., Mcelvaney, H., Mcgivern, K., Mcgovern, J., Mcguinness, E., Mcinerney, N., Mckay, S., Mckee, C., Mckenna, M., Mckenna, N., Mclean, K., Mediratta, S., Medkova, Y., Medzhidov, O., Mehraj, A., Mekhael, M., Mekinde, O., Mellenthin, C., Melucci, A., Mentor, K., Merchant, J., Messias, H., Messeha, M., Meza, C., Mhango, P., Miladinov, M., Milagros Niquen Jimenez, M., Miller, P., Mills, E., Milton, A., Minayeva, O. A., MinHua Zheng, Z., Mischlinger, H., Mo¨ ckli, B., Modi, R., Mohamed, H. M., Mohamed, M., Mohamed Abulghasm, T., Mohammad, S. A., Mohammed, T. O., Mohammed, A., Mohan, H., Mohan, M., Moin, I., Mok, V., Molina, G., Moloney, J., Moneim, J., Monfort Mira, M., Montcusı´ Ventura, B., Montouri, M., Moossdorff, M., Mora-Guzma´ n, I., Moran, B., Mora´ n, R. A. R., Moreno-Ordaz, S., Morera, A´., Morgan, R., Morley, R., Moro-Valdezate, D., Moros, S., Moss, J. -L., Morven, A., Morton, D., Moynihan, A., Moyo´ n, M., Muduli, N., Mugla, N., Mugla, W., Mu¨ ller, P., Mun, G., Mundhada, R., Munir, I., Munoz, F., Mu ~ noz, E., Mu ~ noz, A., Munoz Balderas, D. ~ C., Murgitroyd, E., Murray, V., Murthy, S., ~ Mushiwokufa, W., Mustafa, H., Mustakimov, B., Mutambanengwe, P., Myint, P., Nadkarni, S., Naess, P. A., Nahar, S., Naidoo, P., Nam, R., Nandhra, S., Nanjappa, N., Narasimhan, V., Nardi, W., Nasir, M., Naughton, A., Naumann, D., Navarro, S., Nawaaz Karimbocus, M., Nazir, A., Ndereya, S., Ndong, A., Negoi, I., Nel, D., Nelson, D., Nepal, S., Nugent, T., Nepogodiev, D., Neufeld, J., Ng, J., Ng, D., Ng, C. E., Ngaserin, S., Ngu, L., Ngwenya, E., Fhearaigh, R. N., Nikolousakis, T. -K., Ninkovic, M., Nita, G., Nitschke, C., Noren, E., Noton, T., Novikova, A., Nowinka, Z., Nyakunengwa, T., Nyalundja, A., Nzenwa, I., Ø Kristensen, H., O’Brien, C., O’Brien, L., O’Brien, S., O’Reilly, J., O’Rourke, S., O’Sullivan, M., O’Dwyer, M., Ochieng, L., Oderoha, E., Oh, K. E., O¨ hlberger, L., O¨ lc¸u¨ m, M., Olkina, A., Omkumar, M., Omnitel, B., Oncel Yakar, D., Ong, K., Ong Wei Lin, L., Ooi, R., Ooi, S., Oomman, A., Oon Tyjet, D., Opiyo, S., Oscullo Yepez, J. J., Osei-kuffour, N., Osunronbi, T., Ottlaka´ n, A., Oussama Kacimi, S., Ovaere, S., Ozair, A., Pachler, F., Pai Oo, S., Paiella, S., Panaiotti, L., Panda, N., Pandarinath, S., Pandey, D., Pandrowala, S., Papa Mamadou, F., Paranathala, M., Park, J., Parmar, C., Parvez, A., Pasovic, L., Pasquer, A., Pasumarthy, N., Pata, F., Patel, T., Patel, P., Patel, N., Patel, M., Patron Uriburu, N., Patrone, R., Paul, A., Pavan Kumar, O. M., Pavithran, A., Pedraza Ciro, M., Pellino, G., Peloso, A., Pena~ Gallardo, M. T., Pena Velazquez, A., Perea, J., Pe´rez-Sa´ nchez, L. E., ~ Perra, T., Perrotta, G., Petersson, P., Petra, G., Petrucciani, N., Pickin, C., Pino, V., Pinotti, E., Pinto, F., Plum, P., Podesta, F., Pollini, T., Pompeu Sa´, M., Ponce Leon, F., Ponniah, H. S., Ponte de Sousa, X., Ponton, J., Pontula, A., Popa, M., Portilla, A. L., Posner, F., Post, S., Potolicchio, A., Pouwels, S., Povo, A., Prasad, P., Preciado, S., Preece, R., Proud, D., Pulido Segura, J. A., Puliyath, N., Qui, M., Quimbaya Rodrı´guez, A. S., Raby-Smith, W., Racovit¸a, A., Rad, A., Radwan, R., Rafaih Iqbal, M., Rafik, A., Raguan, B., Rahi, M., Rahiri, J. -L., Rahme, J., Rai, L., Raj, A., Raj Saksena, A., Raja, M., Ramirez, J., Ramzi, J., Ranstam, J., Rao, C., Rashid, A., Ratnayake, B., Rattanasirivilai, K., Raubenheimer, K., Ravikumar, N., Ravn, S., Razoz, N., Rea, W., Regan, A., Rela, M., Remme, A., Rey Chaves, C. E., Reyes, A., Riad, A., Rice, D., Rios Quintana, K., Ritter, A., Roalsø, M., Robinson, D., Rodriguez, J., Rodrı´guez, F., Rodriguez, M. C., Rogers, A., Rohila, J., Romanyuc, D., Romic, I., Rommaneh, M., Rompianesi, G., Rosa, F., Roscio, F., Rose, A., Rotimi, T., Ruiz, H., Ruiz Yucuma, J., Ruiz-U´ car, E., Ruslan, M., Rutega˚ rd, M., Ryan Harper, E., Ryckx, A., Rydbeck, D., Fonseca, E., Sanchez Teran, A., Sanchez Ussa, S., Sandli, O., Sanfey, H., Sanghera, J., Sani, I., Santafe Guerrero, M., Sante Fornasiero, M., Santes Jasso, O., Santos Pereira, I., Santos Sousa, H., Saratzis, A., Sarmiento Alarcon, A., Saumtally, T., Sayyed, R., Schettino, M., Schleimer, L., Schmidt, T., Schondffelt, K., Schwab, M., Scott, A., Searle, H., Sebopelo, L., Seeglier, B., Seishima, R., Semenvov, D., Senent-Boza, A., Sepulveda, J., Serenari, M., Serrano Navidad, M., Sert, I., Sewart, E., Sgro`, A., Shadrina, V., Shah, K., Shahid, F., Shalaby, M., Shankar, B., Shapiro, J., Sharma, L., Sheel, A., Shenfine, A., Shenoy, S., Sherif, A., Shetty, N., Shetty, R., Sia, T. C., Sichimba, D., Siddique, H., Siddiqui, I., Simkens, G., Simoe, J., Simon, H., Sinan, L., Singh, T., Singh, K., Singh, Y., Sinha, L., Siragusa, L., Sluckin, T., Smart, Y. W., Smith, H., Smith, K., Smits, L., Sneep-van Kessel, C., Sohrabi, C., Solo´ rzano Pineda, O., Soma, A., Sooriyapiragasam, L., Søreide, K., Sparavigna, M., Spence, R., Spencer, N., Spiers, H., Spinelli, A., Sprakel, J., Sravanam, S., Srinivasan, M., Srinivasan, R., Staniszewska, A., Stanworth, S. J., Stasinos, K., Steele, R. J. C., Steinholt, I., Steinruecke, M., Stephen, B. -J., Stijns, J., Still, M., Stupalkowska, W., Subba, S., Subbotin, V. V., Sucharitkul, P., Sudarsanam, A., Sudhamsh Reddy, D., Suhardja, T., Suliman, M., Sund, M., Sunilkumar, A., Suresh, N., Sussmes, S., Sutton, P., Syltern, J., Taha, A., Takamizawa, Y., Takoutsing Dongmo, A. B., Tama´ s, T., Tan, L., Tan, J. L., Tan, K., Tan, E., Tan Yong Hui, A., Tanase, A., Tariverdiev, A., Tasnem, A., Tatar, C., Tay, E., Tejedor, P., Tesfaye, G., Tetinou, F., Thorpe, C., Thyø, A., Tlelo Amastal, D., Tolani, M., Tolga Saracoglu, K., To¨ lgyes, T., Tong, J., Torrent Jansa`, L., Toscano Igartua, S., Tovani Palone, M. R., Traff, H., Trevis, J., Tummers, W., Tur, A., Turchenko, I., Uche, V., Uddin, A., Udonsak, N., Ullah, M., Urbonas, T., Uwins, C., Uy Magadia, E., Uzair Qureshi, A., Uzun, K., Vadim, P., Valarche, G., Valdez Gonzalez, R. A., Vallee, M., van Beek, D. -J., van Dalen, A. S., van den Hondel, D., van der stok, E., van Dorp, M., van Oostendorp, S., van Praag, E., van Rees, J., van Silfhout, L., Varga, Z., Varghese, S., Varghese, C., Varghese, J., Vasilica, A. -M., Va´ squez Ojeda, X., Vega, E., Vehler, S., Venchiarutti, R., Vengatesan, S., Venn, M., Verma, D., Vianey Partida Nava, G., Victoria, D., Vieira, P., Vilar Alvarez, M. E., Vinci, D., Viscasillas Palla` s, G., Viswanath, M., Vivanco, J., Vizcaya Rodrı´guez, V., Vo, J., Volchanski, D., Voron, T., Voronovskyi, Y., Vu, J., Wadhwa, M., Wadhwa, S., Wagner, G., Wallace, M., Wang, Y. Y., Wang, J., Wani, A., Wanigasooriya, K., Wanjara, S., Wanjiku, N., Warner, C., Wei Leow, T., Weiser, T., Weisters, M., Wellington, M. J., Wells, C., Wenzelberg, C., Wettstein, D., Wezel, A., Wheldon, L., Widmer, L., Wilson, M., Wigmore, S., Wijayaratne, T., Wijeyaratne, M., 1176 | BJS, B. P. L., 108, Vol., 10 Sá-Marta, No., Sadien, I., Safarinteranya, D., Sagoo, K., Sakata, S., Saladino, E., Saleem, A., Saleem, S., Salehi, M., Salih, S., Sallinen, V., Salvans, S., Sam, Z. H., Samadov, E., Sampaio Alves, M., Sanad, A., Sánchez Wijnhoven, S., Wilkin, R., Williams, E., Willis, F., Winter, D., Wirsik, M. M., Wishah, B., Wong, G., Wong, W. J., Wong, K., Wong, K. -Y., Worku, D., Wright, E., Wright, J., Wroe Wright, O., Xenacki, S., Xia, W., Xu, W., Xu, Z., Yalcinkaya, A., Yang, W., Yang, P. -C., Yanishev, A., Yanzon de la Torre, A., Yao, H., Yaqoob, E., Yen Ling Quake, S., Yeo, D., Yeom, B., Yershov, D., Yiasemidou, M., Yildiz, A., Yiu, A., Yoav, M., Yong, E., Yoshimura, R., Younis, M. U., Younis Ringshawl, Z., Youssef, M., Yue, Y., Yuen, S., Yuldashev, R., Yurttas, C., Yves, B., Zaborowski, A., Zackeri, R., Zafar, A., Zahra, W., Zaidi, A., Zainudin, S., Zakeri, R., Zamora, I., Zamora, A. T., Zawistowski, M., Zbikowska, G., Zegers, W., Zehra, S., Zeyra, A., Zhagniyev, Z., Zhukova, L. G., Zivanovic, M., Zmuc, J., Zope, M., Zubayraeva, A., Zucker., B., Abahuje, E, Abbas, A, Abd El Aziz Abd El Maksoud, M, Abdelhady, A, Abdelhamid, S, Abdelkarem Ahmed Faraj, H, Abdelqader, B, Abdelrahman, T, Abdou, H, Abdullah, A, Abedua Harrison, M, Abem Owusu, E, Aboalazayem, A, Aboulhosn, R, Abu Oda, S, Abubakar, A, Abutaka, A, Acevedo Fontalvo, D, Acuna, S, Adefemi, A, Adegbola, S, Adenuga, T, Adeyeye, A, Adil Hilmi, A, Adisa, A, Aditya, K, Adjeso, T, Aftab, R, Afzal, A, Aggarwal, V, Aggarwal, A, Aguilera, R, Aguilera-Arevalo, M, Aguirre Salamanca, E, Aguirre-Allende, I, Ahari, D, Ahmad, H, Ahmad Rauf, F, Ahmad Zartasht Khan, A, Ahmed, S, Ahmed Fieturi, N, Ahmed Mohamed, S, Ahmed-Bakhsh, Z, Ahsan Javed, M, Akano, L, Akbar, A, Akhbari, M, Akhmedov, P, Aksit, G, Akula, Y, Alagaratnam, A, Al Majid, S, Al Mukhtar, O, Al Omran, H, Alasali, N, Al-Azzawi, M, Al-Habsi, R, Al-Iraqi, H, Al-Naggar, H, Alameer, E, Albirnawi, H, Alderson, D, Aldulaijan, F, Alejandro Miranda Ojeda, R, Alhasan, A, Ali, S, Ali, A, Ali Khan, M, Alimova, Y, Aljanadi, F, Aljubure, R, Allopi, N, Almedbal, H, Almubarak, M, Alqaidoom, Z, Alselaim, N, Alshaar, M, Alshammari, R, Altaf, K, Altiner, S, Altunpak, B, Alvarez Lozada, L, Amal Nahal, E, Amer, A, Amin, K, Aminu, U, Amisi Numbi, N, Amjad, T, Amoah, R, An, Y, Anastasopoulos, N, Andres Urrutia, J, Angarita, F, Angarita, K, Angel Freiria Eiras, M, Antypas, A, Anwar, M, Anwar, H, Apampa, T, Apostolou, K, Aquina, C, Arachchige Adithi Himika Randeni, R, Archila Godinez, M, Arez, O, Arezzo, A, Armonis, P, Arshad, S, Arshad Salman, M, Arshid, A, Arteaga Asensio, P, Arthur, T, Arumuga Jothi, A, Aryo Damara, F, Asensio Gomez, L, Ashcroft, J, Ashraf, S, Asif, A, Atif, M, Attaullah Khan, M, Avellaneda, N, Awad, S, Awadh, M, Axiaq, A, Ayad Mohammed Shuwayyah, A, Ayalew, D, Aytac, E, Azam, F, Azevedo, J, Azhar, B, Aziz, J, Aziz, A, Azzam, A, Baba Ndajiwo, A, Baig, M, Baker, D, Bakko, F, Balachandran, R, Balachandran, G, Balagizi Mudekereza, J, Balai, E, Balci, B, Balduzzi, A, Balhareth, A, Bandyopadhyay, S, Banerjee, D, Bangalore Mahalinga, D, Bankhead-Kendall, B, Bankole, N, Banwell, V, Baris Bengur, F, Baris Ozmen, B, Barnard, M, Barnett, R, Barreras Espinoza, J, Barrios, A, Bass, G, Bass, M, Bausys, A, Bavikatte, A, Bayram, J, Belousov, M, Berardi, A, Beamish, A, Beattie, C, Belia, F, Bellato, V, Bellikatti, S, Benjamens, S, Benlice, C, Bennedsgaard, S, Bennett, S, Bentounsi, Z, Bergenfeldt, H, Bergenfelz, A, Besselink, M, Bhandoria, G, Bhangu, E, Bhatia, M, Bhatti, M, Bilgili, Z, Bislenghi, G, Bisset, C, Biswas, S, Blake, J, Blanco, R, Boccalatte, L, Boden, R, Bojanic, C, Boland, M, Boland, P, Bollen, E, Bonci, E, Boni, L, Booth, A, Booth, R, Borakati, A, Borunda Escudero, G, Bosco, S, Bostrom, P, Botelho De Alencar Ferreira Cruz, P, Bouchagier, K, Bouhuwaish, A, Boutros, M, Boyce, K, Boyle, C, Bradshaw, L, Brandl, A, Brar, A, Brat, G, Brenkman, H, Brennan, C, Brines, C, Brookmyre, A, Brosnan, C, Brouwers, L, Brown, A, Brown, L, Brown, C, Brown, J, Bs, V, Buksh, M, Bunani Emmanuel, M, Burbano, D, Burelli, A, Burke, A, Burke, J, Burlov, N, Burns, A, Burton, O, Butt, A, Buzra Ozkan, B, Cabrera Silva, L, Caicedo, E, Calderbank, T, Cambridge, W, Campelo, G, Can Tatar, O, Carbone, F, Carrano, F, Casallas, D, Casanova Portoles, D, Casciani, F, Cassimjee, I, Castaneda Ramirez, O, Catalan, V, Caviedes, J, Cayetano, L, Ceresoli, M, Chan, M, Chan, V, Chandrasinghe, P, Chapman, S, Chaturvedi, A, Chaudhry, D, Chaudry, H, Chen, H, Cheng, A, Chernykh, M, Cherrie, A, Cheruiyot, I, Cheung, J, Chia, C, Chica, J, Chinai, N, Chirwa, A, Chiwaligo, J, Choi, A, Choi, J, Chowdhury, M, Christopher, E, Christou, N, Chu, T, Chua, D, Chua, H, Chung, C, Cihat Yildirim, A, Cillo, M, Cioffi, S, Claireaux, H, Clermonts, S, Clifford, R, Climent, M, Clynch, A, Coelen, R, Colas-Ruiz, E, Collar, A, Collard, M, Conlon, K, Connelly, T, Connor, K, Cook, J, Correia De Sa, T, Cosgun Acar, N, Costa, T, Couch, D, Cowper, S, Creavin, B, Crook, B, Curell, A, D'Alessio, R, Dale, J, Damgaard Eriksen, J, Dario Martin Gonzalez, I, Darwish, A, Das, M, Das, R, Das, K, Dave, R, David, S, Davies, T, Davis, C, Davison, S, Davletshina, V, Dawidziuk, A, Dawson, A, De Andres Crespo, M, De Berker, H, De Dieu Ngo, P, Dekker, E, De La Caridad Espinosa Luis, R, De Lacy, B, Demartines, N, De Montserrat Medina Sifuentes, A, De Silva, S, Del Rio, C, Delaune, V, Dell, A, Demirbas, I, Demirli Atici, S, Deniz Tepe, M, Derebey, M, Desai, G, Desai, M, Devarakonda, S, Deveras, N, Di Franco, G, Di Martino, M, Di Marzo, F, Diaz, A, Diaz Del Gobbo, G, Diazcastrillon, C, Dick, L, Dickinson, K, Diego, E, Dimasi, I, Ding, A, Dingemans, S, Dixon, L, Dixon, B, Doherty, W, Dooreemeah, D, Donohue, C, Dornseifer, M, Dossa, F, Dossou, W, Drake, T, Drami, I, Drevin, G, Du Plessis, M, Dudi-Venkata, N, Dudley, R, Duffy, S, Duklas, D, Dumbrava, B, Duygu Avlar, F, Dworzynska, A, Ebrahim, W, Ebrahim, A, Efren Lozada Hernandez, E, Ehigie, N, El Boghdady, M, El Hasnaoui, C, El Sheikh, M, El-Hussuna, A, Eldurssi, O, Elfeki, H, Elhadi, M, Elhassan, M, Elhissi, A, Elliot, B, Elsenbroek, C, Elsolh, B, Elson, N, Eltyeb, H, Emerson, H, Emile, S, Endalle, G, English, W, Ercisli, C, Espinosa, G, Essam Abdelraheem, M, Essangri, H, Etienne, P, Evans, M, Evans, T, Ezeme, C, Ezzahraa, F, Fadalla, T, Fagan, J, Fahmy, M, Fairfield, C, Falade, O, Famularo, S, Faqar-Uz-Zaman, F, Farid, Y, Farooq, A, Farooq, H, Farooqui, F, Farquharson, B, Faruqi, A, Faulder, R, Faut, M, Fechner, K, Feenstra, T, Fehervari, M, Fernandez, L, Fernandez Alberti, J, Ferrario, L, Field, D, Fiore, L, Fingerhut, S, Finlayson, S, Fleming, N, Fleming, C, Florial, E, Fok, M, Fokin, D, Foley, M, Forero, M, Forgan, T, Fornasiero, M, Fowler, H, Fowler, G, Franchi, E, Franklin, L, Fredriksson, A, Fruhling, P, Fuentes Navarrette, G, Fulop, A, Furtado, M, Gaarder, T, Galbraith, N, Gallagher, I, Gallo, G, Gana, T, Gaskin, E, Gasparini, M, Gatan, R, Geary, E, Gelaye Wudineh, K, Gemenetzis, G, Georgi, M, Ghalige, H, Ghareeb, W, Ghatwary Tantawy, T, Ghomsi, C, Ghuman, A, Giannakis, P, Giron, F, Gjengedal, K, Gkotsis, E, Glasbey, J, Godahewa, S, Godula, D, Goffredo, P, Goh, S, Golriz, M, Gomez, L, Gomez Gomez, D, Gonzalez, R, Gonzalez, D, Gonzalez Gutierrez, E, Gopar, D, Gordini, L, Gori, A, Gortazar, S, Gousy, N, Gowda, R, Gowda, M, Gqada, J, Grechenig, M, Greer, J, Gregorio, L, Grigorova, A, Grimes, H, Groot, V, Grossman, R, Gruber, R, Gruter, A, Guest, R, Gujjuri, R, Gulcek, E, Gulcu, B, Gull, K, Gulmez, M, Gupta, V, Gutlic, A, Guven, T, Gwatirisa, T, Gwini, G, Gwodog, P, Gysling, S, Habib, M, Hafeez Bhatti, A, Hallesmith, J, Halloran, S, Hamza Sadiq, M, Haney, C, Hanna, N, Hanna, L, Hannington, M, Harbjerg, J, Haribaskaran, D, Harran, N, Harrington, B, Harrison, E, Hasan, R, Hashmi, S, Hassan, M, Hassan, A, Haverkamp, L, Hazen, S, Heer, B, Heil, J, Helliwell, J, Henriksen, N, Henshall, D, Hermanson, M, Hermena, S, Hettiarachchi, D, Hextall, C, Hidalgo, M, Hidayat, H, Hider, A, Higgins, P, Hinchliffe, R, Hirani, D, Hirpara, D, Hisham, I, Hite, M, Hoh, S, Holmberg, C, Holmich, E, Holst, F, Hossam, A, Hossam Elfallal, A, Howard, P, Huaman, E, Huang, Y, Huang, L, Huang, D, Huber, T, Hugh, J, Hughes, J, Huttner, F, Huynh, R, Hylands, A, Iannuzzi, J, Ielpo, B, Iftikhar Talib, A, Ignacio, J, Ignatavicius, P, Ike, S, Ikwu, C, Inama, M, Ing, A, Ingels, A, Isik, A, Islam, N, Ives, I, Al-Hasan, A, Perez Rivera, C, Jacome, F, Jaffer, T, Jagiella-Lodise, O, Jain, M, Jain, K, Jakubauskas, M, Jalal, M, James, H, Jang, Y, Janssen, B, Jansson, H, Jariod-Ferrer, U, Javanmard, H, Javed, S, Jayarajah, U, Jayasuriya, I, Je, J, Jessop, Z, Jia Lin Tang, E, Jiang, H, Jiayan, Y, Jih Huei, T, Jimenez-Rodriguez, R, Joh, D, Johnson, A, Jones, N, Jones, C, Jordan, C, Jose Nunez Ju, J, Jose Pizarro, M, Jose Salazar, C, Joseph, J, Justiniano, C, Kabir, T, Kadhum, M, Kalfountzos, C, Kalogiannaki, E, Kalyanasundaram, K, Kamarajah, S, Kamil Quraishi, M, Kanemitsu, Y, Kapila, A, Kapila, V, Karagiannidis, G, Kashif, M, Kathiravelupillai, S, Kathiravelupillai, A, Katsogridakis, E, Kaur, K, Kaur Sekhon Inderjit Singh, H, Kausur, N, Kawka, M, Keehan, G, Kehlet Watt, S, Kelly, M, Kelvin Egbuchulem, I, Kembuan, G, Khajeh, E, Khaled Elfaitur, A, Khan, M, Khan, S, Khan, D, Khan, H, Khatkar, H, Khatkov, E, Khaw, R, Kim, B, Kishore Siddiraju, K, Kitua, D, Kirimtay, B, Kmezic, S, Knight, S, Koeter, T, Koh, A, Koh Hong Xiang, F, Kojo Anyomih, T, Kok, A, Kokelaar, R, Koliarakis, I, Kolli, S, Kong, J, Konig, D, Koshy, M, Kotze, P, Kourdouli, A, Kowal, M, Kraima, A, Kramer, F, Kryzauskas, M, Kuchynskyi, I, Kuemmerli, C, Kuiper, S, Kumar, S, Kumar, A, Kumar, L, Kumar, H, Kumar, N, Kumar Bandyopadhyay, S, Kumar Garg, P, Kumar Venkatappa, S, Kung, J, Kural, S, Kushairi, A, Kuuzie, E, Kvietkauskas, M, Kwek, I, La, J, Lai, L, Lakpriya, S, Lam, K, Lami, M, Lansdorp-Vogelaar, I, Lapolla, P, Larsen, H, Latif, J, Laudari, U, Laurnezi, A, Lawal, A, Lawday, S, Lederhuber, H, Lednev, A, Lee, R, Van Leerdam, M, Lefevbre, G, Lesmus, M, Leyva Moraga, F, Leyva Moraga, E, Li, H, Li, A, Li, Z, Licardie, E, Light, A, Lightner, A, Lin, A, Lincango, E, Litta, F, Liu, H, Lofthouse, B, Londono, M, Lopes, R, Lopes De Freitas, R, Lopez, L, Lopez, A, Lopez-Gomez, J, Lopez-Pena, G, Lowe, R, Lowe, D, Lowey, M, Loy, G, Lozanovski, V, Luzon, J, Lynn, P, Maccabe, T, Machielsen, A, Mafla Herreria, C, Maggino, L, Mahawar, K, Mahmood, D, Mahmoud, M, Mahtani, K, Maitra, I, Maji, S, Majiet, I, Mal, L, Malherbe, J, Malhotra, K, Malkomes, P, Man, E, Manan Sheikh, A, Manjunath, S, Manzano Nunez, R, Manzoor, S, Maqsood, R, Marchegiani, G, Marchegiani, F, Marin, D, Marin, A, Marks, I, Marson, E, Martensen, A, Martin, D, Martin Martin, G, Martin-Perez, B, Martinez, P, Marwaha, P, Mashauri, C, Mashbari, H, Masior, L, Masri, R, Masud, L, Masudi, S, Mateu Calabuig, G, Math, S, Matrachisia, A, Mayol, J, Mazingi, D, Mazzotta, A, Mcalinden, J, Mccabe, G, Mccolm, L, Mcelvaney, H, Mcgivern, K, Mcgovern, J, Mcguinness, E, Mcinerney, N, Mckay, S, Mckee, C, Mckenna, M, Mckenna, N, Mclean, K, Mediratta, S, Medkova, Y, Medzhidov, O, Mehraj, A, Mekhael, M, Mekinde, O, Mellenthin, C, Melucci, A, Mentor, K, Merchant, J, Messias, H, Messeha, M, Meza, C, Mhango, P, Miladinov, M, Milagros Niquen Jimenez, M, Miller, P, Mills, E, Milton, A, Minayeva, O, MinHua Zheng, Z, Mischlinger, H, Mockli, B, Modi, R, Mohamed, H, Mohamed, M, Mohamed Abulghasm, T, Mohammad, S, Mohammed, T, Mohammed, A, Mohan, H, Mohan, M, Moin, I, Mok, V, Molina, G, Moloney, J, Moneim, J, Monfort Mira, M, Montcusi Ventura, B, Montouri, M, Moossdorff, M, Mora-Guzman, I, Moran, B, Moran, R, Moreno-Ordaz, S, Morera, A, Morgan, R, Morley, R, Moro-Valdezate, D, Moros, S, Moss, J, Morven, A, Morton, D, Moynihan, A, Moyon, M, Muduli, N, Mugla, N, Mugla, W, Muller, P, Mun, G, Mundhada, R, Munir, I, Munoz, F, Munoz, E, Munoz, A, Munoz Balderas, D, Murgitroyd, E, Murray, V, Murthy, S, Mushiwokufa, W, Mustafa, H, Mustakimov, B, Mutambanengwe, P, Myint, P, Nadkarni, S, Naess, P, Nahar, S, Naidoo, P, Nam, R, Nandhra, S, Nanjappa, N, Narasimhan, V, Nardi, W, Nasir, M, Naughton, A, Naumann, D, Navarro, S, Nawaaz Karimbocus, M, Nazir, A, Ndereya, S, Ndong, A, Negoi, I, Nel, D, Nelson, D, Nepal, S, Nugent, T, Nepogodiev, D, Neufeld, J, Ng, J, Ng, D, Ng, C, Ngaserin, S, Ngu, L, Ngwenya, E, Fhearaigh, R, Nikolousakis, T, Ninkovic, M, Nita, G, Nitschke, C, Noren, E, Noton, T, Novikova, A, Nowinka, Z, Nyakunengwa, T, Nyalundja, A, Nzenwa, I, Kristensen, H, O'Brien, C, O'Brien, L, O'Brien, S, O'Reilly, J, O'Rourke, S, O'Sullivan, M, O'Dwyer, M, Ochieng, L, Oderoha, E, Oh, K, Ohlberger, L, Olcum, M, Olkina, A, Omkumar, M, Omnitel, B, Oncel Yakar, D, Ong, K, Ong Wei Lin, L, Ooi, R, Ooi, S, Oomman, A, Oon Tyjet, D, Opiyo, S, Oscullo Yepez, J, Osei-Kuffour, N, Osunronbi, T, Ottlakan, A, Oussama Kacimi, S, Ovaere, S, Ozair, A, Pachler, F, Pai Oo, S, Paiella, S, Panaiotti, L, Panda, N, Pandarinath, S, Pandey, D, Pandrowala, S, Papa Mamadou, F, Paranathala, M, Park, J, Parmar, C, Parvez, A, Pasovic, L, Pasquer, A, Pasumarthy, N, Pata, F, Patel, T, Patel, P, Patel, N, Patel, M, Patron Uriburu, N, Patrone, R, Paul, A, Pavan Kumar, O, Pavithran, A, Pedraza Ciro, M, Pellino, G, Peloso, A, Pena Gallardo, M, Pena Velazquez, A, Perea, J, Perez-Sanchez, L, Perra, T, Perrotta, G, Petersson, P, Petra, G, Petrucciani, N, Pickin, C, Pino, V, Pinotti, E, Pinto, F, Plum, P, Podesta, F, Pollini, T, Pompeu Sa, M, Ponce Leon, F, Ponniah, H, Ponte De Sousa, X, Ponton, J, Pontula, A, Popa, M, Portilla, A, Posner, F, Post, S, Potolicchio, A, Pouwels, S, Povo, A, Prasad, P, Preciado, S, Preece, R, Proud, D, Pulido Segura, J, Puliyath, N, Qui, M, Quimbaya Rodriguez, A, Raby-Smith, W, Racovita, A, Rad, A, Radwan, R, Rafaih Iqbal, M, Rafik, A, Raguan, B, Rahi, M, Rahiri, J, Rahme, J, Rai, L, Raj, A, Raj Saksena, A, Raja, M, Ramirez, J, Ramzi, J, Ranstam, J, Rao, C, Rashid, A, Ratnayake, B, Rattanasirivilai, K, Raubenheimer, K, Ravikumar, N, Ravn, S, Razoz, N, Rea, W, Regan, A, Rela, M, Remme, A, Rey Chaves, C, Reyes, A, Riad, A, Rice, D, Rios Quintana, K, Ritter, A, Roalso, M, Robinson, D, Rodriguez, J, Rodriguez, F, Rodriguez, M, Rogers, A, Rohila, J, Romanyuc, D, Romic, I, Rommaneh, M, Rompianesi, G, Rosa, F, Roscio, F, Rose, A, Rotimi, T, Ruiz, H, Ruiz Yucuma, J, Ruiz-Ucar, E, Ruslan, M, Rutegard, M, Ryan Harper, E, Ryckx, A, Rydbeck, D, Sa-Marta, E, Sadien, I, Safari Nteranya, D, Sagoo, K, Sakata, S, Saladino, E, Saleem, A, Saleem, S, Salehi, M, Salih, S, Sallinen, V, Salvans, S, Sam, Z, Samadov, E, Sampaio Alves, M, Sanad, A, Sanchez Fonseca, S, Sanchez Teran, A, Sanchez Ussa, S, Sandli, O, Sanfey, H, Sanghera, J, Sani, I, Santafe Guerrero, M, Sante Fornasiero, M, Santes Jasso, O, Santos Pereira, I, Santos Sousa, H, Saratzis, A, Sarmiento Alarcon, A, Saumtally, T, Sayyed, R, Schettino, M, Schleimer, L, Schmidt, T, Schondffelt, K, Schwab, M, Scott, A, Searle, H, Sebopelo, L, Seeglier, B, Seishima, R, Semenvov, D, Senent-Boza, A, Sepulveda, J, Serenari, M, Serrano Navidad, M, Sert, I, Sewart, E, Sgro, A, Shadrina, V, Shah, K, Shahid, F, Shalaby, M, Shankar, B, Shapiro, J, Sharma, L, Sheel, A, Shenfine, A, Shenoy, S, Sherif, A, Shetty, N, Shetty, R, Sia, T, Sichimba, D, Siddique, H, Siddiqui, I, Simkens, G, Simoe, J, Simon, H, Sinan, L, Singh, T, Singh, K, Singh, Y, Sinha, L, Siragusa, L, Sluckin, T, Smart, Y, Smith, H, Smith, K, Smits, L, Sneep-Van Kessel, C, Sohrabi, C, Solorzano Pineda, O, Soma, A, Sooriyapiragasam, L, Soreide, K, Sparavigna, M, Spence, R, Spencer, N, Spiers, H, Spinelli, A, Sprakel, J, Sravanam, S, Srinivasan, M, Srinivasan, R, Staniszewska, A, Stanworth, S, Stasinos, K, Steele, R, Steinholt, I, Steinruecke, M, Stephen, B, Stijns, J, Still, M, Stupalkowska, W, Subba, S, Subbotin, V, Sucharitkul, P, Sudarsanam, A, Sudhamsh Reddy, D, Suhardja, T, Suliman, M, Sund, M, Sunilkumar, A, Suresh, N, Sussmes, S, Sutton, P, Syltern, J, Taha, A, Takamizawa, Y, Takoutsing Dongmo, A, Tamas, T, Tan, L, Tan, J, Tan, K, Tan, E, Tan Yong Hui, A, Tanase, A, Tariverdiev, A, Tasnem, A, Tatar, C, Tay, E, Tejedor, P, Tesfaye, G, Tetinou, F, Thorpe, C, Thyo, A, Tlelo Amastal, D, Tolani, M, Tolga Saracoglu, K, Tolgyes, T, Tong, J, Torrent Jansa, L, Toscano Igartua, S, Tovani Palone, M, Traff, H, Trevis, J, Tummers, W, Tur, A, Turchenko, I, Uche, V, Uddin, A, Udonsak, N, Ullah, M, Urbonas, T, Uwins, C, Uy Magadia, E, Uzair Qureshi, A, Uzun, K, Vadim, P, Valarche, G, Valdez Gonzalez, R, Vallee, M, Van Beek, D, Van Dalen, A, Van Den Hondel, D, Van Der Stok, E, Van Dorp, M, Van Oostendorp, S, Van Praag, E, Van Rees, J, Van Silfhout, L, Varga, Z, Varghese, S, Varghese, C, Varghese, J, Vasilica, A, Vasquez Ojeda, X, Vega, E, Vehler, S, Venchiarutti, R, Vengatesan, S, Venn, M, Verma, D, Vianey Partida Nava, G, Victoria, D, Vieira, P, Vilar Alvarez, M, Vinci, D, Viscasillas Pallas, G, Viswanath, M, Vivanco, J, Vizcaya Rodriguez, V, Vo, J, Volchanski, D, Voron, T, Voronovskyi, Y, Vu, J, Wadhwa, M, Wadhwa, S, Wagner, G, Wallace, M, Wang, Y, Wang, J, Wani, A, Wanigasooriya, K, Wanjara, S, Wanjiku, N, Warner, C, Wei Leow, T, Weiser, T, Weisters, M, Wellington, M, Wells, C, Wenzelberg, C, Wettstein, D, Wezel, A, Wheldon, L, Widmer, L, Wilson, M, Wigmore, S, Wijayaratne, T, Wijeyaratne, M, Wijnhoven, B, Wilkin, R, Williams, E, Willis, F, Winter, D, Wirsik, M, Wishah, B, Wong, G, Wong, W, Wong, K, Worku, D, Wright, E, Wright, J, Wroe Wright, O, Xenacki, S, Xia, W, Xu, W, Xu, Z, Yalcinkaya, A, Yang, W, Yang, P, Yanishev, A, Yanzon De La Torre, A, Yao, H, Yaqoob, E, Yen Ling Quake, S, Yeo, D, Yeom, B, Yershov, D, Yiasemidou, M, Yildiz, A, Yiu, A, Yoav, M, Yong, E, Yoshimura, R, Younis, M, Younis Ringshawl, Z, Youssef, M, Yue, Y, Yuen, S, Yuldashev, R, Yurttas, C, Yves, B, Zaborowski, A, Zackeri, R, Zafar, A, Zahra, W, Zaidi, A, Zainudin, S, Zakeri, R, Zamora, I, Zamora, A, Zawistowski, M, Zbikowska, G, Zegers, W, Zehra, S, Zeyra, A, Zhagniyev, Z, Zhukova, L, Zivanovic, M, Zmuc, J, Zope, M, Zubayraeva, A, Zucker, B, Aguilera-Arévalo, M -L, Aguirre Salamanca, E J, Al-Asali, N, Altıner, S, Alvarez Lozada, L A, Anastasopoulos, N -A, Andrés Urrutia, J, Angarita, K -L, Ángel FreirÍa Eiras, M, Anwar, M A, Apampa, T O, Archila Godínez, M I, Arteaga Asensio, P C, Bankole, N D A, Barreras Espinoza, J A, Bhatti, M T, Bonci, E -A, Borunda Escudero, G E, Bosco, S J, Boström, P, Botelho de Alencar Ferreira Cruz, P, Caicedo, E Y, Castañeda Ramírez, O A, Catalán, V, Chen, H W, Chowdhury, M R, Chua, H W, Coelen, R -J, Colás-Ruiz, E, Correia de Sá, T, Coşgun Acar, N, D’Alessio, R, David, S O, de Andres Crespo, M, de Berker, H, de Dieu Ngo, P, de la Caridad Espinosa Luis, R, de Lacy, B, de Montserrat Medina Sifuentes, A, del Rio, C, Demirbaş, I, Díaz, Á, Diaz del Gobbo, G, Diaz-Castrillon, C, du Plessis, M C, Dumbrava, B -D, Efrén Lozada Hernández, E, Fernández Alberti, J, Forero, M P, Fredriksson, Å, Fülöp, A, Gatan, R G, Gortázar, S, Gregório, L, Grüter, A, Gülçek, E, Hafeez Bhatti, A B, Hoh, S M, Hölmich, E, Hüttner, F, Alhasan, A J M S, Perez Rivera, C J, Jácome, F, Jariod-Ferrer, Ú, José, J, José Núñez Ju, J, José Pizarro, M, Khan, M F, Kırımtay, B, Kmezić, S, Koëter, T, König, D, Leyva Moraga, F A, Li, H L, Londoño, M A, Lopes de Freitas, R, López, A I, Mafla Herrería, C A, Manzano Nuñez, R, Marín, D, Martín Martín, G, Masior, Ł, Möckli, B, Mohamed, H M, Mohammad, S A, Mohammed, T O, Montcusí Ventura, B, Mora-Guzmán, I, Morán, R A R, Morera, Á, Moss, J -L, Moyón, M, Müller, P, Muñoz, F, Muñoz, E, Muñoz, A, Muñoz Balderas, D C, Ng, C E, Fhearaigh, R N, Nikolousakis, T -K, Kristensen, H Ø, O’Brien, L, O’Brien, S, O’Reilly, J, O’Rourke, S, O’Sullivan, M, O’Dwyer, M, Oh, K E, Öhlberger, L, Ölçüm, M, Oscullo Yepez, J J, Osei-kuffour, N, Ottlakán, A, Pavan Kumar, O M, Peña Gallardo, M T, Peña Velazquez, A, Pérez-Sánchez, L E, Pompeu Sá, M, Ponniah, H S, Ponte de Sousa, X, Portilla, A L, Pulido Segura, J A, Quimbaya Rodríguez, A S, Racoviţă, A, Rahiri, J -L, Rey Chaves, C E, Roalsø, M, Rodríguez, F, Rodriguez, M C, Ruiz-Úcar, E, Rutegård, M, Sá-Marta, E, Sam, Z H, Emile, Sameh H, Sánchez Fonseca, S, Sgrò, A, Sia, T C, Smart, Y W, Sneep-van Kessel, C, Solórzano Pineda, O, Stephen, B -J, Takoutsing Dongmo, A B, Tamás, T, Tan, J L, Thyø, A, Tölgyes, T, Torrent Jansà, L, Tovani Palone, M R, Valdez Gonzalez, R A, van Beek, D -J, van Dalen, A S, van den Hondel, D, van der stok, E, van Dorp, M, van Oostendorp, S, van Praag, E, van Rees, J, van Silfhout, L, Vasilica, A -M, Vásquez Ojeda, X, Vilar Alvarez, M E, Viscasillas Pallàs, G, Vizcaya Rodríguez, V, Wang, Y Y, Wellington, M J, Wirsik, M M, Wong, W J, Wong, K -Y, Wright, O Wroe, Yang, P -C, Yanzon de la Torre, A, Younis, M U, Zamora, A T, and Surgery
Subjects: Adult, Male, medicine.medical_specialty, Biomedical Research, Coronavirus disease 2019 (COVID-19), International Cooperation, Practice Patterns, Commission, Global Health, Health Services Accessibility, Perioperative Care, Education, Surgeon, COVID-19, surgery, perioperative care, Medical, Pandemic, Humans, Medicine, Practice Patterns, Physicians', Graduate, Pandemics, Surgeons, Health Resource, Infection Control, Physicians', Surgical Procedures, business.industry, General surgery, Middle Aged, Operative, Education, Medical, Graduate, Surgical Procedures, Operative, Perioperative care, Health Resources, Surgery, Female, business, Human
Abstract: Background Coronavirus disease 2019 (COVID-19) was declared a pandemic by the WHO on 11 March 2020 and global surgical practice was compromised. This Commission aimed to document and reflect on the changes seen in the surgical environment during the pandemic, by reviewing colleagues’ experiences and published evidence. Methods In late 2020, BJS contacted colleagues across the global surgical community and asked them to describe how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had affected their practice. In addition to this, the Commission undertook a literature review on the impact of COVID-19 on surgery and perioperative care. A thematic analysis was performed to identify the issues most frequently encountered by the correspondents, as well as the solutions and ideas suggested to address them. Results BJS received communications for this Commission from leading clinicians and academics across a variety of surgical specialties in every inhabited continent. The responses from all over the world provided insights into multiple facets of surgical practice from a governmental level to individual clinical practice and training. Conclusion The COVID-19 pandemic has uncovered a variety of problems in healthcare systems, including negative impacts on surgical practice. Global surgical multidisciplinary teams are working collaboratively to address research questions about the future of surgery in the post-COVID-19 era. The COVID-19 pandemic is severely damaging surgical training. The establishment of a multidisciplinary ethics committee should be encouraged at all surgical oncology centres. Innovative leadership and collaboration is vital in the post-COVID-19 era.
Published: 2021
Full Text: View/download PDF

39. Two Case Reports of Fibroid Treatment with Ulipristal Acetate Before In Vitro Fertilization

Author: Teresa Gastañaga-Holguera, Isabel Campo Gesto, Ignacio Cristóbal García, Marta Calvo Urrutia, Virginia González González, and Marta Vidaurreta Lázaro
Subjects: medicine.medical_specialty, Pregnancy, In vitro fertilisation, Obstetrics, business.industry, Uterine fibroids, Sterility, medicine.medical_treatment, Gold standard, Myoma, medicine.disease, female genital diseases and pregnancy complications, chemistry.chemical_compound, chemistry, Ulipristal acetate, medicine, business, Benign Uterine Neoplasm
Abstract: Uterine fibroids are common benign uterine neoplasms in women of reproductive age and pregnancy desire. Several surgical approaches for symptomatic fibroids are available, such as surgical or pharmacologic treatments. We report two cases of fibroids treatment with ulipristal acetate (UPA) in women with primary sterility. The first case reports a successful in vitro fertilization (IVF) after UPA as an alternative treatment to reduce the size of fibroids in a patient with two previous abdominal myomectomies, resulting in an evolutive pregnancy. The second patient is a clinical case of a successful IVF after UPA treatment in a patient with a submucous fibroid which induced myoma migration leading to its prolapse. Even though myomectomy appears to be the gold standard treatment for fibroids in women with reproductive desires, UPA treatment could be considered in those patients at high surgical risk, although more clinical series are needed to establish the safety of UPA as treatment in those women.
Published: 2021
Full Text: View/download PDF

40. Prevalence and Determinants of Tobacco Smoking Among Low-Income Urban Adolescents

Author: Augusto Matamala-Bezmalinovic, Javier Mallol, Marilyn Urrutia-Pereira, Manuel J Mallol-Simmonds, Lucas Calderón-Rodríguez, and Francisco Osses-Vergara
Subjects: Male, Pulmonary and Respiratory Medicine, Low income, medicine.medical_specialty, Passive smoking, Adolescent, medicine.disease_cause, 03 medical and health sciences, 0302 clinical medicine, 030225 pediatrics, Environmental health, Prevalence, Tobacco Smoking, Humans, Immunology and Allergy, Medicine, Child, Original Research, business.industry, Public health, Smoking, Cross-Sectional Studies, 030228 respiratory system, Pediatrics, Perinatology and Child Health, Female, Tobacco Smoke Pollution, business
Abstract: Background: Tobacco-smoking in children is one of the most crucial public health concerns, which could be highly prevalent in underprivileged populations. Methods: A cross sectional, random sampling survey was conducted to determine the prevalence of current tobacco-smoking and related risk factors among adolescents living in a low-income area of Santiago de Chile. Results: Of the 2,747 adolescents participating in the study, 24.0% [95% confidence interval (CI) 22.3–25.5] were current smokers, with no significant difference between girls and boys. Factors associated with current smoking were as follows: positive attitude to smoking cigarettes offered by peers [odds ratio (OR) 8.0; 95% CI 5.7–11.3, P
Published: 2021
Full Text: View/download PDF

41. Exploring the Collateral Damage of the COVID-19 Pandemic on Stroke Care

Author: Roland Faigle, Eric Aldrich, Erin Lawrence, Clotilde Balucani, Karen Yarbrough, Victor C. Urrutia, J. Ricardo Carhuapoma, Adrian Goldszmidt, Elizabeth Marsh, Brenda Johnson, Anna Aycock, Susan Groman, Chad Schrier, Joseph K. Canner, Linda Toral, and Michael S. Phipps
Subjects: medicine.medical_specialty, Subarachnoid hemorrhage, Coronavirus disease 2019 (COVID-19), medicine.medical_treatment, 030204 cardiovascular system & hematology, Stroke care, 03 medical and health sciences, Patient Admission, 0302 clinical medicine, Acute care, Pandemic, medicine, Humans, Thrombolytic Therapy, Stroke, Cerebral Hemorrhage, Ischemic Stroke, Retrospective Studies, Thrombectomy, Advanced and Specialized Nursing, Maryland, business.industry, COVID-19, Retrospective cohort study, Thrombolysis, Subarachnoid Hemorrhage, medicine.disease, Quality Improvement, Acute Disease, Emergency medicine, Neurology (clinical), Cardiology and Cardiovascular Medicine, business, 030217 neurology & neurosurgery
Abstract: Background and Purpose: During the coronavirus disease 2019 (COVID-19) pandemic, the various emergency measures implemented to contain the spread of the virus and to overcome the volume of affected patients presenting to hospitals may have had unintended consequences. Several studies reported a decrease in the number of stroke admissions. There are no data on the impact of the COVID-19 pandemic on stroke admissions and stroke care in Maryland. Methods: A retrospective analysis of quality improvement data reported by stroke centers in the State of Maryland. The number of admissions for stroke, overall and by stroke subtype, between March 1 and September 30, 2020 (pandemic) were compared with the same time period in 2019 (prepandemic). Median last known well to hospital arrival time, the number of intravenous thrombolysis and thrombectomy were also compared. Results: During the initial 7 months of the pandemic, there were 6529 total admissions for stroke and transient ischemic attack, monthly mean 938 (95% CI, 837.1–1038.9) versus prepandemic 8003, monthly mean 1156.3 (CI, 1121.3–1191.2), P P P =0.507. Conclusions: Our findings suggest that the COVID-19 pandemic adversely affected the acute care of unrelated cerebrovascular emergencies.
Published: 2021
Full Text: View/download PDF

42. Assessment of geriatrics outcomes in the cardiac intensive care unit

Author: Usman I. Choudhry, Matthew C. Langston, Carly Fabrizio, Neil J. Wimmer, Luis Urrutia, and Keshab Subedi
Subjects: Geriatrics, education.field_of_study, medicine.medical_specialty, business.industry, Mortality rate, Population, Retrospective cohort study, Intensive care unit, law.invention, law, Intensive care, Emergency medicine, medicine, Coronary care unit, education, business, Coronary intensive care
Abstract: Objective: Critically ill older adults greater than or equal to 80 years old are routinely admitted to contemporary cardiac intensive care units (CICU). Little has been reported about their outcomes when compared to the general CICU population. The primary aim of this study was to compare the mortality, length-of-stay, and disposition outcomes of elderly patients (greater or equal to 80 years old) admitted to the CICU with a younger cohort (less than 80 years old). Methods and Results: A single-center, retrospective cohort study was conducted including 6,194 adult patients admitted to a cardiovascular intensive care unit in Newark, Delaware, from July 1, 2012, to June 30, 2019. Coronary intensive care unit (CICU) mortality, CICU length-of-stay and discharge disposition were compared between elderly patients (greater than or equal to 80 years old) and younger patients (less than 80 years old), adjusted for comorbidities. We observed increased mortality for elderly patients (OR 1.686, CI 1.361-2.090, p
Published: 2021
Full Text: View/download PDF

43. Poor re-epithelialization following corneal collagen crosslinking with riboflavin-uva for advanced bullous keratopathy: Case series

Author: B. Benito-Pascual, Pedro Arriola-Villalobos, M. Ariño-Gutiérrez, and M.T. Iradier-Urrutia
Subjects: medicine.medical_specialty, genetic structures, Riboflavin, Visual Acuity, Visual scale, 03 medical and health sciences, 0302 clinical medicine, Re-Epithelialization, Re-epithelialization, Ophthalmology, Humans, Medicine, Severe pain, Surgical treatment, Aged, High rate, Photosensitizing Agents, business.industry, Middle Aged, Corneal tomography, eye diseases, Cross-Linking Reagents, 030221 ophthalmology & optometry, Bullous keratopathy, Female, Collagen, sense organs, business
Abstract: Summary Objective To assess safety and efficacy of corneal collagen crosslinking (CXL) for advanced bullous keratopathy (BK). Material and methods Eight eyes of eight patients subjected to Dresden CXL protocol. Inclusion criteria: BK history of at least one year, severe pain and no indication for keratoplasty due to poor visual prognosis. Variables: best corrected visual acuity (BCVA), pain (decimal visual scale), central corneal thickness (CCT) by tomography (Pentacam®, Oculus Inc, Germany), corneal bullae and complications. Results Seven women and one man of median age 77.00 (range 58–79) years. The median follow-up was 7 (range 5–7) months. BCVA remained unchanged through follow-up. A significant decrease in pain was observed at the end of the follow-up period (median 6, range 5–6 vs. median 0, range 0–4, P = 0.05). Corneal tomography could only be performed in three cases, due to poor vision or image quality. A reduction in mean CCT was observed in the first post procedural month (from 708.33 ± 140.48 to 627 ± 136.89 μm). In all eight cases, the absence of corneal bullae only persisted for two months after CXL. In six patients, corneal re-epithelialization after CXL was poor; in four of these eyes, the problem was resolved with topical treatment, but in the remaining two eyes, amniotic membrane transplant and mechanical debridement were required. Conclusions In this uncontrolled small case series, CXL treatment improved pain in patients with advanced BK. However, the high rate of poor re-epithelialization requiring surgical treatment observed in one third of cases makes this treatment controversial.
Published: 2021
Full Text: View/download PDF

44. Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike protein vaccine: a randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)

Author: Juan M. Fernández-Ávila, Jorge L. Azor-Hernández, Cristina O. Chávez-Chong, Klaudia Urrutia-Pérez, Lianne del Toro-Lahera, Joel Quintana-Guerra, Verena Muzio-Gonzalez, Enrique Noa-Romero, Yenima Martín-Bauta, Sergio del Valle-Piñera, Elisangela Tablada-Ferreiro, Rossana Remedios-Reyes, Gilda Lemos-Pérez, Zadis Navarro-Rodríguez, Marjoris Piñera-Martínez, Jacqueline Bizet-Almeida, Nabil A. Ali-Mros, Francisco Hernández-Bernal, Leonardo Lobaina-Lambert, Mayara Ramírez-Domínguez, José L. Rodríguez-Reinoso, Karen Urrutia-Pérez, Miladys Limonta-Fernández, Maria C. Ricardo-Cobas, Marel Alonso-Valdes, Ariel Palenzuela-Díaz, Marta Ayala-Ávila, Jeniffer Rodríguez-Nuviola, and Elizabeth Colina-Ávila
Subjects: Clinical trial, Vaccination, medicine.medical_specialty, Titer, business.industry, Vaccination schedule, Internal medicine, Immunogenicity, medicine, Seroconversion, Adverse effect, Placebo, business
Abstract: AimTo evaluate the safety and immunogenicity of a SARS-CoV-2 recombinant spike protein vaccine (Abdala), administered intramuscularly in different strengths and vaccination schedules.MethodA phase 1-2, randomized, double-blind, placebo-controlled trial was done. Subjects were randomly distributed in 3 groups: placebo, 25 and 50µg RBD. The product was applied intramuscularly, 0.5 mL in the deltoid region. During the first phase, two immunization schedules were studied: short (0-14-28 days) and long (0-28-56 days). In phase 2, only the short scheme was evaluated. The main endpoints were: safety and proportion of subjects with seroconversion of anti-RBD IgG antibodies to SARS-CoV-2. Blood samples were collected in several points according to the corresponding vaccination schedule to determine the level of RBD-specific IgG antibodies (seroconversion rates and geometric mean of the titers), the percentage of inhibition of RBD-ACE-2 binding and levels of neutralizing antibodies.ResultsThe product was well tolerated. Severe adverse events were not reported. Adverse reactions were minimal, mostly mild and local (from the injection site), resolved in the first 24-48 hours without medication. In phase 1, at day 56 (28 days after the third dose of the short vaccination schedule, 0-14-28 days) seroconversion of anti-RBD IgG was seen in 95.2 % of the participants (20/21) for the 50μg group and 81 % of the participants (17/21) for the 25μg group, and none in the placebo group (0/22); whereas neutralizing antibodies to SARS-CoV-2 were seen in 80 % of the participants (8/10) for the 50μg group and 94.7% of the participants (18/19) for the 25μg group. For the long schedule, at day 70 (14 days after the third dose) seroconversion of anti-RBD IgG was seen in 100% of the participants (21/21) for the 50μg group and 94.7% of the participants (18/19) for the 25μg group, and none in the placebo group (0/22); whereas neutralizing antibodies to SARS-CoV-2 were seen in 95 % of the participants (19/20) for the 50μg group and 93.8% of the participants (15/16) for the 25μg group In phase 2, at day 56 seroconversion of anti-RBD IgG was seen in 89.2% of the participants (214/240) for the 50μg group, 77.7% of the participants (185/238) for the 25μg group, and 4.6% in the placebo group (11/239); whereas neutralizing antibodies to SARS-CoV-2 were seen in 97.3% of the participants (146/150) for the 50μg group and 95.1% of the participants (58/61) for the 25μg group.ConclusionAbdala vaccine against SARS-CoV-2 was safe, well tolerated and induced humoral immune responses against SARS-CoV-2 among adults from 19 to 80 years of age.Trial registration / Review protocolRPCEC00000346. Cuban Public Clinical Trial Registry (WHO accepted Primary Registry).Available from: https://rpcec.sld.cu/en/trials/RPCEC00000346-EnInformation about the ethical aspects and IRB approvalThe protocol was approved by the Ethic Committee of the participating hospital and by the Cuban Regulatory Authority (Center for State Control of Drugs, Medical Devices and Equipment).Summary boxCOVID-19 is a serious global health problem. Vaccines are urgently needed to protect humanity. Multiple vaccine candidates are currently being evaluated. The article shows promising safety and immunogenicity results for a vaccine candidate, based on the recombinant RBD subunit of the spike protein.
Published: 2021
Full Text: View/download PDF

45. Liraglutide hospital discharge trial: A randomized controlled trial comparing the safety and efficacy of liraglutide versus insulin glargine for the management of patients with type 2 diabetes after hospital discharge

Author: Gianluca Iacobellis, Maria A. Urrutia, Patricia C. Gomez, Juan D. Palacios, Priyathama Vellanki, Karla W. Z. Coronado, Georgia Davis, Francisco J. Pasquel, Rodolfo J. Galindo, Limin Peng, Bonnie S. Albury, Isabel Anzola, Javier M. Farias, Guillermo E. Umpierrez, Ajay Chaudhuri, Mireya C. Perez-Guzman, Maya Fayfman, Saumeth Cardona, and Alexandra Migdal
Subjects: Blood Glucose, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Insulin Glargine, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Gastroenterology, Article, law.invention, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Randomized controlled trial, law, Weight loss, Internal medicine, Internal Medicine, medicine, Clinical endpoint, Humans, Hypoglycemic Agents, Adverse effect, Glycated Hemoglobin, Liraglutide, Insulin glargine, business.industry, medicine.disease, Hospitals, Patient Discharge, Treatment Outcome, Diabetes Mellitus, Type 2, Drug Therapy, Combination, medicine.symptom, business, Weight gain, medicine.drug
Abstract: AIM: To compare a glucagon-like peptide-1 receptor agonist with basal insulin at hospital discharge in patients with uncontrolled type 2 diabetes in a randomized clinical trial. METHODS: A total of 273 patients with glycated haemoglobin (HbA1c) 7%–10% (53–86 mol/mol) were randomized to liraglutide (n = 136) or insulin glargine (n = 137) at hospital discharge. The primary endpoint was difference in HbA1c at 12 and 26 weeks. Secondary endpoints included hypoglycaemia, changes in body weight, and achievement of HbA1c
Published: 2021
Full Text: View/download PDF

46. Neurological manifestations temporally associated with SARS-CoV-2 infection in pediatric patients in Mexico

Author: Alejandra González-Duarte, Matilde Ruiz-García, Marta Urrutia-Osorio, Esteban Camacho-Mendoza, Gustavo Rosales-Pedraza, Patricia Herrera-Mora, Luis Dávila-Maldonado, and Areli Estela Sánchez-Morales
Subjects: Male, Pediatrics, medicine.medical_specialty, Ataxia, Adolescent, Encephalopathy, Acute ischemic stroke, Optic neuritis, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, 030212 general & internal medicine, Child, Stroke, Mexico, Pandemics, Children, Myositis, Guillain-Barre syndrome, business.industry, SARS-CoV-2, Infant, Newborn, COVID-19, Infant, Anti-NMDA-R encephalitis, General Medicine, medicine.disease, Guillain-Barré syndrome, Child, Preschool, Acute cerebellar ataxia, Pediatrics, Perinatology and Child Health, Etiology, Original Article, Neurology (clinical), medicine.symptom, business, Rhabdomyolysis, 030217 neurology & neurosurgery, Encephalitis
Abstract: Purpose To describe the temporal association of specific acute neurological symptoms in pediatric patients with confirmed SARS-CoV-2 infection between May and August 2020. Methods We performed a recollection of all the clinical and laboratory data of patients having acute neurological symptoms temporally associated with SARS-CoV-2 infection at a third-level referral hospital in Mexico City (Instituto Nacional de Pediatría). Patients in an age group of 0–17 years with acute neurological signs (including ascending weakness with areflexia, diminished visual acuity, encephalopathy, ataxia, stroke, or weakness with plasma creatinine kinase (CK) elevation) were evaluated. Results Out of 23 patients with neurological manifestations, 10 (43%) had a confirmed SARS-CoV-2 infection. Among the infected patients, 5 (50%) were males aged 2–16 years old (median age 11.8 years old). Four (40%) patients confirmed a close contact with a relative positive for SARS-CoV-2, while 6 (60%) cases had a history of SARS-CoV-2–related symptoms over the previous 2 weeks. The following diagnoses were established: 3 cases of GBS, 2 of ON, 2 of AIS, one of myositis with rhabdomyolysis, one ACA, and one of anti-NMDA-R encephalitis. Conclusions Neurological manifestations temporally associated with SARS-CoV-2 infection were noticed in the pediatric population even without respiratory symptoms. In this study, 2 of 6 symptomatic patients had mild respiratory symptoms and 4 had unspecific symptoms. During this pandemic, SARS-CoV-2 infection should be considered as etiology in patients with acute neurological symptoms, with or without previous respiratory manifestations, particularly in teenagers.
Published: 2021

47. Applying data mining on customer relationship management system to discover forgotten effects

Author: Dra. Carolina Nicolas, Roberto Ahumada, Angélica Urrutia, and Fabiola Rojo
Subjects: Statistics and Probability, Knowledge management, Computer science, business.industry, General Engineering, 02 engineering and technology, Customer relationship management, 03 medical and health sciences, 0302 clinical medicine, Artificial Intelligence, 030221 ophthalmology & optometry, 0202 electrical engineering, electronic engineering, information engineering, 020201 artificial intelligence & image processing, business
Abstract: Companies need to know customer preferences for decision-making. For this reason, the companies take into account the Customer Relationship Management (CRM). These information systems have the objective to give support and allow the management of customer data. Nevertheless, it is possible to forget causal relationships that are not always explicit, obvious, or observables. The aim of this study on new methodologies for finding causal relationships. This research used a data analysis methodology of a CRM. The traditional analysis method is the Theory of Forgotten Effects (TFE), which is considered in this work. The new approach proposed in this article is to use Data Mining Algorithms (DMA) like Association Rules (AR) to discover causal relationships. This study analyzed 5,000 users’ comments and opinions about a Chilean foods industry company. The results show that the DMA used in this work obtains the same values as the TFE. Consequently, DMA can be used to identify non-obvious comments about products and services.
Published: 2021
Full Text: View/download PDF

48. Household pollution and COVID-19: irrelevant association?

Author: Marilyn Urrutia-Pereira, Carlos Augusto Mello-da-Silva, and Dirceu Solé
Subjects: Pulmonary and Respiratory Medicine, Pollution, medicine.medical_specialty, Isolation (health care), Working poor, Refugee, media_common.quotation_subject, Immunology, Disease, Heating, 03 medical and health sciences, 0302 clinical medicine, Environmental health, Epidemiology, Pandemic, medicine, Humans, Immunology and Allergy, media_common, Transients and Migrants, Refugees, business.industry, Working Poor, COVID-19, General Medicine, Prognosis, Wood, Manure, Coal, Socioeconomic Factors, 030228 respiratory system, Air Pollution, Indoor, Etiology, Tobacco Smoke Pollution, business, 030215 immunology
Abstract: Evidence supports the link between air pollution and coronavirus disease 2019 (COVID-19). Therefore, exposure to indoor pollution (IDP) is likely to be associated with the disease. The poor, refugees, and migrant workers who live in feeble conditions are the most vulnerable. The pandemic has caused many people to remain indoors, especially at-risk individuals (e.g., the elderly, diabetics, obese, cardiac, and chronic lung disease patients). Home isolation may be an underlying factor to other health problems among these populations if the place where they are socially isolating is not adequately ventilated. Therefore, understanding the consequences of the relationship between IDP and the COVID-19 pandemic is essential.
Published: 2021
Full Text: View/download PDF

49. Multicriteria Methodology for Open Space Analysis

Author: Rufino Hernandez Minguillón, Olatz Grijalba Aseguinolaza, and Nagore Urrutia del Campo
Subjects: Urban Studies, business.industry, Computer science, Geography, Planning and Development, Environmental resource management, Space (commercial competition), business, Computer Science Applications, Diversity (business)
Abstract: This paper describes an urban analysis method for the evaluation of the diversity of open spaces. Diversity is understood as the variety of options that a public space offers to the users, giving them the opportunity to choose the area which best suits their needs, activities, and personal preferences. The method facilitates an environmental quality assessment and comparative evaluation between spaces. Decision support tools based on data analysis are developed to facilitate technical urban design decisions. The methodology is based on a multi-criteria analysis of a public square in Madrid, Spain. Field measurements of climatic data and thermal properties of materials, the activities carried out by people and their location, as well as factors related to urban design are collated in the analysis. Data are complimented with bioclimatic and simulation tools. The analysis identifies differentiated thermal profiles, as well as patterns of use of the space. This enables the identification of specific locations currently favored by citizens and the microclimatic and spatial variety of the square.
Published: 2021
Full Text: View/download PDF

50. Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis

Author: Martínez Rivera, Carlos, Garcia-Olivé, Ignasi, Urrutia-Royo, Blanca, Basagaña-Torrento, Maria, Rosell, Antoni, Abad Capa, Jorge, and Universitat Autònoma de Barcelona
Subjects: Pulmonary and Respiratory Medicine, Budesonide, Male, medicine.medical_specialty, Pulmonary function, Exacerbation, Injections, Subcutaneous, Case Report, Churg-Strauss Syndrome, Antibodies, Monoclonal, Humanized, Gastroenterology, Bronchospasm, 03 medical and health sciences, chemistry.chemical_compound, Leukocyte Count, 0302 clinical medicine, Internal medicine, Forced Expiratory Volume, Eosinophilic, Medicine, Humans, Anti-Asthmatic Agents, Asthma, lcsh:RC705-779, business.industry, Severe eosinophilic asthma, Eosinophilic granulomatosis with polyangiitis, Granulomatosis with Polyangiitis, 030208 emergency & critical care medicine, Benralizumab, lcsh:Diseases of the respiratory system, Eosinophil, Middle Aged, respiratory system, medicine.disease, respiratory tract diseases, Eosinophils, medicine.anatomical_structure, Treatment Outcome, 030228 respiratory system, chemistry, Disease Progression, medicine.symptom, business, Granulomatosis with polyangiitis, medicine.drug
Abstract: Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a disease that is associated with severe uncontrolled eosinophilic asthma. Eosinophils play an important pathogenic role in the development of both diseases. Benralizumab is an antieosinophilic monoclonal antibody that binds to the α subunit of the human interleukin 5 receptor that is expressed on the surface of the eosinophil and basophil. We present the first case of rapid improvement in symptoms and lung function during admission for exacerbation of a severe eosinophilic asthma associated with EGPA. Case presentation A 57-year-old man diagnosed with severe eosinophilic asthma associated to EGPA was admitted to the Pulmonology Department due to severe bronchospasm. At admission he presented 2300 eosinophils/µl. Despite intensive bronchodilator treatment, intravenous methylprednisolone at a dose of 80 mg/d, oxygen therapy, and budesonide nebulization, the patient continued to present daily episodes of bronchospasm. Ten days after admission, with blood eosinophil levels of 1700 cells/µl, benralizumab 30 mg sc was administered. That day, the Forced Expiratory Volume in the first second (FEV1) was 28% of the theoretical value (1150 ml). AT three days, FEV1 increased to 110 ml (31%). On the 9th day FEV1 was 51% (2100 ml). The blood eosinophil level on the 9th day was 0 cells/µl. Conclusions The rapid improvement of FEV1 is in line with studies based on clinical trials that found improvement after two days in peak flow and one phase II study that showed rapid response in exacerbation of asthma in the emergency room. The antieosinophilic effect at 24 h and the effect in different tissues determine the rapid improvement and the potential advantage of benralizumab in the treatment of EGPA. This case suggests the usefulness of benralizumab in patients with EGPA and eosinophilic severe asthma who show bronchospasm refractory to conventional treatment during a hospitalization due to asthma exacerbation.
Published: 2021

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

1,723 results on '"Urrutia, A."'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources